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Summary
An In situ Hybridisation method was developed and utilised to evaluate and pinpoint 
the cellular presence of IL2 and IL4 mRNA transcripts produced by Thl and Th2 
subsets respectively of activated T cells in frozen tissue sections of Lewis heart 
allografts from rejecting DA recipients and from recipients tolerised by Cyclosporin, 
Blood Transfusion and Antibody therapy regimens. A panel of monoclonal 
antibodies was used on the tissue sections initially and confirmed the presence of the 
activated T cells known to express the cytokines being studied. The Polymerase 
Chain Reaction was used next on tissue homogenates from the same samples to 
establish the presence of IL2 and IL4 mRNA transcripts and showed that IL2 mRNA 
sequences were present in all rejecting samples, but not in all tolerised samples, 
whereas with the exception of some day 2 grafts, IL4 transcripts were present in all 
other rejecting grafts, and also in CsA and Transfused grafts but not in all Antibody 
treated grafts. As the presence of cytokine transcripts had been established by PCR, 
the ISH method was utilised to attempt to pinpoint specific cellular production of the 
IL2 and IL4 transcripts in the frozen sections of the tissue. All rejecting grafts and 
grafts from Transfused recipients were found to be positive for IL2 transcripts 
whereas CsA treated recipients grafts were negative, and Antibody treated recipients 
grafts found to be variable. IL4 transcripts were found in 50% of the rejecting grafts 
only, suggesting that ISH is not sensitive enough to record low levels of mRNA 
expression and that the use of both the ISH and PCR methods in tandem would be 
more beneficial in intragraft cytokine transcription detection.
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Chapter 1
Introduction
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1.1 Transplantation
Organ transplantation is becoming increasingly common as a form of treatment for 
end-stage failure of organs including the kidneys, liver, heart and lung. A continuing 
problem in clinical transplantation is the loss of transplanted organs and tissues 
through immunological rejection. As a consequence, a major research effort is 
directed towards understanding the mechanisms of allograft rejection and developing 
strategies for inducing specific tolerance towards the allograft.
1.2 Histocompatibility and transplantation
The molecular and cellular processes which culminate in rejection of a transplanted 
tissue are initiated by differences in cell surface molecules, termed histocompatibility 
antigens (Gorer et al, 1938), between donor and recipient. The major 
histocompatibility complex (MHC) antigens, which are the predominant cell surface 
antigens responsible for allograft rejection, include a group of antigens 
(MHC class I) which are expressed on virtually all nucleated cell types in the body, 
and provoke strong antibody responses. A related group of antigens (MHC class II), 
with a more limited and species-dependent cellular distribution, has the capacity to 
provoke massive cellular proliferation when two populations of class Il-incompatible 
lymphocytes are cultured together (the in vitro mixed lymphocyte reaction or MLR).
1.2.1 Structure and function of MHC molecules
The overall structure of class I and class II MHC molecules is broadly similar. Both 
are members of the Immunoglobulin (Ig) superfamily (Like CD4, CD8 and T-cell 
receptor (TCR) molecules (Halloran et al, 1993), and are transmembrane
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glycoprotein heterodimers. MHC class I has one heavy chain non-covalently 
associated with a p2 microglobulin subunit (P2m) that lacks a membrane anchor. 
The heavy chain comprises three structurally distinct extracellular domains 
designated a l ,  a2  and a3. The membrane distal a l  and a2 domains are associated 
with the presentation of peptides and the membrane proximal oc3 domain has been 
shown to be associated with the binding of CDS molecules on T lymphocytes 
(T cells)(Germain and Marguiles, 1993).
Class II MHC molecules consist of two non-identical glycoprotein chains, 
a  and p which are non-covalently bound; they are of similar length and each has two 
extracellular domains classed as a l  and a2, and pi and p2. The a l  and p i distal 
domains form the peptide binding groove while the p2 proximal domain is the site of 
interaction with CD4 molecules on T cells.
The crystal structure of the peptide binding grooves of both class I and 
class II MHC molecules was resolved using x-ray diffraction analysis and showed 
that although the basic core structures of the molecules were similar, the length of 
the bound peptides in the grooves differed, optimally 9 amino acids for class I 
(Rotzschke and Falk, 1991) and 13-26 amino acids for class II (Chicz et al, 1992). 
These peptide fragments are recognised by the CD8/TCR complex and CD4/TCR 
complex cell surface molecules respectively on T cells thus initiating the activation of 
these cells.
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1.3 Cellular basis of allograft rejection
Sir Peter Medawar was a pivotal figure in the development of the modem era of 
transplantation. He observed, from both clinical cases and experimental studies, that 
cellular infiltration of the graft was characteristic of tissue rejection. He described the 
phenomenon of accelerated, or second-set, rejection of repeated grafts from the 
same donor and he showed that second-set rejection could be transferred by 
lymphoid cells but not serum (Medawar, 1944 & Billingham et al, 1954). The role of 
alloantibody in graft rejection was thought to be neghgible and research effort 
mainly focused on the cellular component of the rejection response.
It is now apparent that the presence of pre-formed alloantibody is 
detrimental to an allograft and causes hyperacute rejection. In clinical 
transplantation, hyperacute rejection is excluded by a pre-transplant cross match, and 
the contribution to rejection by the development of alloantibodies post-transplant 
has probably been underestimated. Recent experimental studies ( Morton et al, 1993) 
have demonstrated the capacity of transferred alloantibody alone to cause rapid 
rejection in rat cardiac allograft recipients treated with anti-CD4 antibody. 
Nevertheless, it must be appreciated that the development of alloantibodies is 
entirely dependent on the activation of T helper cells in the rejection response.
1.3.1 Cellular components of rejecting grafts
Medawar’s observations that the transfer of lymphoid cells effected second set 
rejection were supported by experiments using neonatally thymectomised mice
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(Miller, 1962) and congenitally athymie nude rodent (Corley and Kindred, 1977) 
models which demonstrated the inability of the host to effect rejection in the absence 
of T cells. Reconstitution of lethally irradiated hosts by adoptive transfer of T cells 
was enough to restore cardiac allograft rejection (Hall et al, 1978) in the absence of 
alloantibody production and the speed of rejection was found to be dependent upon 
the number of transferred T cells. These experiments suggested that alloantigen 
reactive T cells were the mediators of graft rejection.
The use of radiolabelled lymphocytes and macrophages (Olewole et al,
1981) and the availabihty of monoclonal antibodies(mAbs), specific for a range of 
leucocyte antigens enabled the graft infiltrating cells to be studied much more 
closely ( Bishop et al, 1986). The kinetics of leucocyte infiltration and the phenotypic 
analysis of the graft infiltrate were studied by several groups e.g. Armstrong et al, 
(1987), and M'^Whinnie et al, (1986), and it was shown that the infiltrate was highly 
heterogeneous comprising macrophages, CD8 positive( CD 8\ cytotoxic) and CD4 
positive (CD4^, helper) T cells, with a preponderance of the CD8^ phenotype in 
rejecting allografts compared to non-rejecting grafts (Bradley et al, 1985 & Padberg 
et al, 1988).
An essential role for C D 8^ cells in the mediation of allograft rejection 
was proposed following the isolation of cytotoxic T cells from rejecting organ 
allografts (von Wilhbrand and Hayry, 1978 & Hayry et al, 1979). It was postulated 
that alloantigen reactive CD8^ cytotoxic T cells, which produced Interferon- 
gamma(IFNy) (Klein et al, 1982 & Nathan et al, 1983) could therefore activate host
17
macrophages which could lead to a delayed type hypersensitivity (DTH) response, 
causing graft rejection. Sensitised C D 8^ cells were shown to restore rejection of 
kidney (Lowry et al, 1983), pancreas (Prowse et al, 1985), thyroid (Warren and 
Pemberley, 1985), and heart grafts (Gurley et al, 1986 & Herbert and Roser, 1987), 
and were the only effective subset in restoring rejection of class I MHC incompatible 
rat skin grafts (Lowry et al, 1985). Rosenberg et al, (1986), noted that C D 8 ^  cells 
mediated rejection of skin grafts that expressed a mutant class I protein. However, a 
central role for C D 8^ cells in rejection was questioned following a set of 
experiments which showed that T cell deficient mice could reject fully mismatched 
skin allografts only if they were reconstituted with purified syngeneic CD8 C D 4 ^  
cells, and not CD8^ CD4 T cells (Loveland et al, 1982 & Loveland and McKenzie,
1982) while Cobbold and Waldmann, (1986), showed either CD8^ or C D 4 ^  cells 
could mediate rejection of fully disparate skin grafts in previously sensitised mice, 
but that the rejection episode required C D 4^ cell involvement. This synergy of 
CD4^ and C D 8 ^  cells in rejection was also noted by other groups using MHC 
disparate heart graft models ( Hall et al, 1985).
Studies using different rat strains, previously categorised as ‘high 
responders’ or ‘low responders’ by their abihty to make cytotoxic lymphocytes and 
alloantibody (Butcher et al, 1982) showed that in ‘low responder’ strains e.g. 
DA(RTU^  ^), organ allografts bearing only class I MHC mismatches could not be 
rejected but class II MHC incompatible grafts could, whereas in ‘high responder’ 
strains e.g. Lewis(RTl') where high titres of alloantibodies occurred, class I or class 
n  incompatibilities could be rejected. Experiments carried out by Sapori et al, (1985)
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and Salomon et al, (1984), showed that in ‘low responders’ the proliferation of 
C D 8 ^  cells was poor without C D 4^ cell help, but conversely, in ‘high responder’ 
strains, C D 8^ cells could be activated independently of C D 4^ cells but that their 
proliferation could be enhanced dramatically by the presence of C D 4^  cells. The 
vigorous alloantibody response, only seen in the ‘high responder’ hosts bearing 
class I disparate organ grafts showed that alloantibody, produced by host B 
lymphocytes(B cells) could have an important role in acute rejection in non­
sensitised recipients, which challenged the widely held view that acute rejection was 
mediated by cellular effector mechanisms.
The use of congenitally athymic PVG (RTT) nude rats as T cell deficient 
hosts in adoptive transfer experiments helped to clarify the picture. These rats are 
incapable of making functional T cells (Bell et al, 1987) and are therefore unable to 
reject allografts from mismatched donors (Mason and Simmonds, 1988). Bolton et 
al, (1989), showed that nude PVG(RTP) rats, which had been intravenously injected 
with purified syngeneic CD4^ T cells and engrafted with an allogeneic DA(RTU''^) 
kidney, rapidly rejected the graft at a time comparable to animals given unseparated 
T cells in a similar system and that the transfer of purified naive CD8^ T cells alone, 
irrespective of the numbers used could not cause the rejection of the kidney allograft 
in this system. This showed that naive C D 8^ cells needed C D 4^ cell help for their 
proliferation and activation.
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1.3.2 The central role of CD4 T cells
Experiments using conventional euthymie rats in transplants between various strains 
bearing MHC class I disparities showed that T cell deficient animals could only reject 
class I MHC disparate skin or heart grafts if C D 8^ cells were included in an 
adoptively transferred naive cell population, but these C D 8^ cells were only 
effective if they had C D 4^ cell help (Bell et al, 1990). Cobbold et al, (1984), using 
monoclonal antibodies(mAbs) to deplete hosts of CD8^ and C D 4^  cells, found that 
the elimination of C D 8^ cells did not affect the survival time of fuUy MHC 
disparate skin grafts but that depletion of C D 4^ cells caused prolonged graft 
survival. These results were echoed by Morton et al, (1993), who showed that 
although anti-CD8 antibody was highly efficient at eliminating C D 8^ cells from rat 
PVG(RT1“) recipients of PVG R8 class I MHC disparate heart grafts, it didn’t 
affect graft survival time and the grafts were consequently destroyed in the absence 
of a C D 8 ^  cell population. Conversely, administration of an anti-CD4 antibody 
cocktail only partially depleted the T cell population, but significantly prolonged 
graft survival time. From these and previous experiments, the general overall view 
was that the T cell requirements for allograft rejection depended on the type of tissue 
transplanted e.g. skin graft (non-vascularised ) or vascularised organ graft, and the 
degree of genetic disparity between donor and recipient (Hao et al, 1987).
The complex and integrated immunologic response seen in allograft 
rejection has been shown to involve both humoral and cellular effector mechanisms, 
and in the latter, the C D 8^ cell subset plays an important but lesser role whereas the
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C D 4 ^  cell subset orchestrates the complex series of signals and events that 
eventually lead to graft destruction.
1.4 CD4 and CDS T cells
Like MHC class I and class II molecules, both CD4 and CDS molecules are members 
of the Immunoglobulin(Ig) superfamily. AH mature T cells express one or the other 
of these surface markers and this determines their binding specificity - to class II and 
class I MHC molecules respectively, thus restricting the T cells to recognition of 
antigens associated with these molecules (Aversa and Hall, 1991, Doyle and 
Strominger, 1987 & Norment et al, 1988).
The CD8 molecule is dimeric in structure, either ap  or a a  chained with a 
cytoplasmic domain, a membrane anchor, an Ig domain and an N-terminal v-like 
domain containing loops forming contact points for engagement to MHC class I 
molecules. The CD4 molecule is a rod-like chain consisting of four Ig domains, an 
intracellular portion and a membrane anchor. It has two N-terminal domains whose 
function is to engage the p chain of MHC class II molecules (Halloran et al, 1993). 
The CD4 and CD 8 molecules act as MHC class II and class I restriction elements 
respectively for the T cell receptor(TCR)-CD3 complex. The TCR consists of either 
ap  or y5 chain heterodimers which are associated with a group of molecules known 
as the CD3 complex. Interaction of the TCR with either alloantigen or a self-MHC 
expressing foreign antigenic peptide is facihtated by CD4 or CD8 molecules binding 
to regions of class II or class I MHC molecules respectively. The process of TCR 
binding to specific antigen transmits a signal to the cell cytosol, triggering a cascade
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of intracellular events including tyrosine phosphorylation to which CD4 and CDS 
molecules contribute by their association with the p56'^  ^ molecule leading to the 
activation of the T cell (Aversa and Hall, 1991 & Sundstrom and Ansari, 1995).
As the interaction of the TCR-CD3 complex and CD4 and CDS accessory 
molecules with antigen and MHC complexes are of a low affinity, other accessory 
molecules have been found to be necessary to increase the overall avidity of the 
T cell for its target. These include adhesion molecules on T cells e.g. CD2 and LFAl 
which interact with their hgands LFA3 and ICAMl respectively on antigen 
presenting cells(APCs) and CD2S and its B cell hgand B7/BB1. These cell surface 
molecule interactions between T cells and target cells are not only responsible for the 
close approximation of these cells but the cytoplasmic domains present in these 
molecules also transmit co-stimulatory signals necessary to ensure activation of the T 
cell (Sundstrom and Ansari, 1995).
1.4.1 T cell responses to alloantigen
It has been shown that the T cell response to allogeneic molecules is much greater 
than that to nominal protein antigens (up to several hundred times greater) 
(Auchencloss, 1995). The strength of response is extremely important in 
transplantation immunology as the transplant is the only situation in which both 
donor and recipient APCs are available to stimulate the immune response. The cause 
of this powerful immune response has been shown to be a combination of different 
factors including the ability of T cells to recognise allogeneic MHC antigens as intact 
molecules independent of bound peptides (Shoskes and Wood, 1994). The ability of
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the immune system to respond to foreign antigens is governed by recognition by 
responding T cells, of peptides derived from processed antigens in association with 
MHC molecules. APCs collect and process both endogenous and exogenous protein 
antigens into smaller peptides for presentation to CD4^ and C D 8^ cells in the 
context of their expressed class II and class I MHC molecules respectively 
(Sundstrom and Ansari, 1995).
There are two distinct pathways by which protein antigens are degraded 
intracellularly for presentation in association with class I and class II molecules. 
Endogenous antigens are assembled in the endoplasmic reticulum and in the presence 
of transporter molecules e.g. TAPI and TAP2, the peptides are carried to the MHC 
molecules bringing about the formation of MHC class I /peptide complexes on the 
cell surface with the peptide occupying the binding groove. In contrast, exogenous 
antigens which have been engulfed by the recipient MHC are partly degraded in the 
endocytic vesicles. These vesicles then bring the peptide into contact with MHC 
molecules as they emerge from the endoplasmic reticulum. The MHC class 
n/peptide complex then travels to the cell surface where like class I molecules, the 
peptide occupies the binding groove. Swain, (1983), showed that C D 8 ^  cells could 
recognise endogenously synthesised antigen in the context of self class I MHC 
molecules and could also respond directly to allogeneic class I MHC molecules 
whereas C D 4^ cells recognised exogenously derived antigen in the context of self 
class II MHC and could also respond directly to allogeneic MHC class II molecules. 
This abihty of T cells to engage and respond to allogeneic molecules directly has
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been shown to be responsible for the strong proliferative response to alloantigen and 
the subsequent acute rejection of allografts (Shoskes and Wood, 1994).
Although C D 4^ cells are incapable of recognising intact allogeneic class I 
molecules directly, it had been postulated that host APCs could process class I 
alloantigens that had been shed by the graft shortly after transplantation and present 
them as antigenic MHC class I peptide fragments in the antigen binding groove of 
self MHC class II molecules (Golding and Singer, 1984). Several more recent 
studies using rats corroborated this theory showing that recipient T cells could be 
primed by immunisation with peptides derived from allogeneic MHC class I 
molecules and bring about accelerated graft rejection (Fangman et al, 1992). This 
‘indirect’ method of presentation of exogenously derived antigenic peptides is similar 
to that used by recipient B cells which process donor class I MHC molecules and 
present the peptides to C D 4^ cells in the context of self class II MHC molecules 
which in turn give cognate help to the B cell to produce MHC class I specific 
alloantibodies.
The central event that initiates allograft rejection is the host TCR/CD3 
complex binding to the target MHC molecules containing allopeptides closely 
followed by the selective binding of the CD4 or CD8 co-receptors with their 
respective ligands on MHC class II or class I molecules respectively. After 
engagement, and the series of complex intracellular signalling events that occur, 
activation and proliferation of the T cell follows, accompanied by the generation of
24
cytokines which promote their growth and function and are central to the 
achievement of T cell dependent immune responses.
1.5 Cytokines and transplantation
Since it became apparent that both cellular and humoral reactions to protein antigens 
were dependent on the function of T helper cells, the question arose as to how the 
same cells could be involved in diverse immune responses. The answer lay in the 
realisation in the 1970s, that T lymphocytes activated in culture by mitogens, 
secreted soluble proteins into the culture supernatant that had the capacity to 
promote different cellular functions in different in vitro assay systems; a protein that 
led to B lymphocyte proliferation was termed B cell growth factor while another 
protein, T cell growth factor stimulated T cell proliferation.
These various soluble proteins which have a short half-life are collectively 
called Cytokines and regulate all important biological processes e.g. cell growth and 
activation, tissue repair, inflammation, immunity etc. They are produced,usually in 
low concentrations, by cells to engage protein receptors on other cells in the local 
environment. They interact in a self regulating network which if disrupted can have 
dramatic effects on the immune response. For this reason, many groups have studied 
the highly complex interactions between cytokines in transplantation to try and 
ascertain the influence of these proteins in graft rejection or tolerance 
(Dallman, 1993).
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1.5.1 Thl and Th2 helper ceils
In 1986 Mossmann found that cloned lines of C D 4^ cells could be classified into 
two groups, termed Thl and Th2, based on the cytokines they produced and their 
related functional activities. The subset model evolved to include many new 
cytokines, and Thl cells are now classified by their production of Interleukin 2(IL2), 
Interferon-gamma(IFNy) and Tumour necrosis factor-beta(TNFp) whereas Th2 cells 
produce Interleukins 4, 5, 6, 10 and 13 (IL4, IL5, IL6, ILIO and IL13) (Mosmann et 
al, 1986, Mosmann and Coffman, 1989 & Mosmann and Sad, 1996). Human Thl 
and Th2 clones produce similar cytokine patterns although ILIO is also secreted by 
Thl cells in humans and by activated macrophages (Somasse et al, 1991). A third 
phenotype, ThO which produces a combination of the cytokines characteristic of the 
Thl and Th2 subsets has also been described (Mosmann et al, 1991), and has been 
proposed to be a precursor of Thl and Th2 clones as it was reported to be 
predominant in the earliest stages of some alloresponses.
In the rat, Thl and Th2 clones have not yet been fully characterised, but 
peripheral C D 4^  cells have been divided into two populations based on the 
expression of the CD45RC molecule. CD45RC'"^^ C D 4^ cells have been shown to 
produce IL2 and IFNy and have similar actions to mouse and human Thl clones 
whereas CD45RC'°'^ C D 4^ cells produce IL4 and act like Th2 clones in mice and 
humans (Josien et al, 1995).
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1.5.2 Differentiation of Thl and Th2 subsets
Thl and Th2 cells are thought to derive from the same T cell precursor, a mature 
naive C D 4^  cell which, upon stimulation with antigen, produces mainly IL2. The 
differentiation of effector Thl and Th2 phenotypes may then proceed through a ThO 
stage of unrestricted cytokine gene expression before expressing a more restricted 
cytokine profile (Kelso, 1995). Several factors have been shown to influence the 
differentiation into Thl or Th2 lineages.
Cytokines themselves are the most potent inducing stimuh and it has been 
shown that IL12 chiefly, and to a lesser extent IFNy, primarily induce Thl 
development. IL12 is produced by macrophages and dendritic cells, and only Thl 
cells and uncommitted recently activated cells bear functional IL12 receptors (Szabo 
et al, 1995). IFNy promotes Thl development by enhancing IL12 secretion by the 
macrophages and preserving IL12 Receptor(IL12R) expression on C D 4 ^  cells 
(Guler et al, 1996). Th2 development is induced by IL4 which is produced in small 
amounts by the T cell itself during its initial activation (Schmitz et al, 1994). C D 8^  
ceUs have also been shown in mice and humans to secrete Thl and Th2 - like 
cytokine patterns, termed Tel and Tc2. These subsets can be derived under similar 
conditions to Thl and Th2 cells and once committed to either the Tel or Tc2 subset, 
neither subset can be converted to the other (Sad et al, 1995).
Two other factors have been shown to influence the Thl/Th2 balance. 
Costimulatory molecules on APCs have been shown to influence Thl and Th2 
differentiation. Antibodies against B7-1 and B7-2, two structurally related proteins
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which interact with T cells via their specific receptor CD28 have been reported to 
selectively inhibit the development of Thl and Th2 responses respectively 
(Thompson, 1995). Antigen dose or concentration has also been implicated, with 
low levels of antigen reported to induce Thl development, and high levels, Th2 
development (Hosken et al, 1995).
1.5.3 Functions of Thl and Th2 cells
The functions of Thl and Th2 cells have been shown to correlate with then- 
distinctive cytokine repertoires. Thl cells are involved in cell mediated reactions e.g. 
IL2 can activate cytotoxic cell functions and IFNy induces DTH reactions, and these 
cells can also provide some B cell help whereas Th2 cells are primarily responsible 
for promoting humoral activity e.g. IL4-induced switching of B cells to 
Immunoglobulin E(IgE) production and eosinophil production and activation by IL5 
(Mosmann and Sad, 1996).
The cytokine products of Thl and Th2 cells are mutually antagonistic i.e. 
IFNy, a Thl product, inhibits the proliferation of Th2 cells while IL4 and ELIO, both 
Th2 products can block cytokine synthesis by Thl cells (Nickerson et al, 1994). 
Many naturally occurring immune responses have clearly shown either Thl or Th2 
cell dominance. Studies of the murine model of Leishmania major infection showed 
that resistance to, and recovery from, the disease, was associated with IFNy 
synthesis (Thl) whereas disease progression was associated with IL4 synthesis 
(Th2). Furthermore, the course of the infection could be altered by treatment with
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antibodies to IL4 or IFNy or by administration of recombinant DL12(rIL12) early in 
the infection (Kelso, 1995).
These results, together with studies on allergies and autoimmune diseases 
showed that IFNy and IL4 could exert opposing effects on a wide variety of immune 
responses e.g. Isotype switching in B cells and macrophage function and 
development of T cell cytokine profiles, and supported the idea that the dominant 
cytokine of the T cell response could be dependent on the cytokine environment 
during T cell activation.
1.5.4 Cytokines and allograft rejection
The contribution of cytokines to the pathways culminating in graft rejection has been 
extensively studied and, as a result, the Thl/Th2 paradigm has been extended to 
encompass the view that graft rejection is mediated primarily by Thl cytokines, 
while the dominance of Th2 cytokines in the graft should predispose towards graft 
tolerance. Results of many studies do not conform to this concept; for example, 
while it has been clearly shown that DTH and cytotoxic T cell activity participate in 
graft rejection, characterised by intragraft expression of the Thl cytokines IL2 and 
IFNy (O’Connell et al, 1993), the presence of the Th2 cytokines IL4 and ILIO has 
also been noted (Dallman et al, 1991 & Takeuchi et al, 1992), suggesting that graft 
rejection may be driven by a mixture of the action of Thl and Th2 cells or by ThO 
cells which produce many different cytokines, and not by the Thl hneage alone 
(Dallman, 1995). The strong association of EL2 expression with rejection has led to 
experiments being carried out using IL2 knockout mice whose IL2 gene has been
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functionally silenced. The results of these experiments showed that despite a lack of 
detectable IL2, these mice still rejected their grafts. Analysis of the intragraft 
cytokine profile of these mice showed the presence of IFNy, IL4 and IL7 (Nickerson 
et al, 1994), thus indicating that the presence of more than one T cell growth factor, 
albeit not necessarily from a T cell source may be needed to support proliferation of 
alloreactive T cells and rejection. Candidates may be IL7, which has been shown to 
enhance cytotoxic T cell proliferation (Alderson et al, 1990), and IL 15, which is 
known to bind to the (3 and possibly y chains of the IL2R and support the 
proliferation and activation of CD4^ and CD8^ T cells (Nickerson et al, 1994).
These results seemed to suggest that although the expression of Thl 
cytokines e.g. IL2 is strongly associated with rejection, it may not necessarily be 
required for the rejection process. Krams et al, (1992), detected the messenger 
ribonucleic acid(mRNA) of the Th2 cytokines IL4 and IL5 in 80% of rejecting renal 
allograft biopsies and IL2 mRNA (Thl) in only 20% of these cases, and a TH2 
response, categorised by the presence of IL4, has been reported to accompany 
delayed rejection (Hancock et al, 1993). It is likely that factors such as time scales, 
strain and species differences and organ-specific responses account for discrepancies 
in experimental results and the lack of consensus concerning the roles of particular 
cytokines in allograft rejection.
1.5.5 Cytokines and tolerance to alloantigen
Examination of the cytokine profiles expressed in recipients rendered tolerant to 
allografts by either pretransplant donor specific blood transfusion(DSBT), brief
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cyclosporin A(CsA) treatment or high, but not low dose anti-CD4 mAb therapy has 
shown near universal decrease in expression of the Thl type cytokine genes (IL2 and 
IFNy) as well as persistent and/or enhanced expression of the Th2 type cytokine 
genes (IL4 and ILIO) in the graft and recipient spleen, leading to the hypothesis that 
immune deviation from a Thl to a Th2 type cytokine profile may play a major role in 
long-term graft acceptance (Takeuchi et al, 1992). Bugeon et al, (1992), noted a 
reduction of EL2 and IFNy mRNA expression in recipients made tolerant by 
pretransplant DSBT, while Hancock et al, (1993), demonstrated reduced expression 
of IFNy, IL2R and TNFa and increased IL4 mRNAs in rat heart grafts from 
recipients made tolerant by anti-CD4 mAb treatment. Morris et al, (1995), found 
reduced expression of IL2 but enhanced ILIO mRNA in heart allografts of recipients 
pre-treated with anti-CD4 mAh. Takeuchi et al, (1992), observed differential 
activation of the Th2 lineage in CsA treated allograft recipients although this may 
have been due to the drugs capacity to block IL2 transcription, thus muting a Thl- 
like response. The role of ILIO in tolerance induction has been studied only relatively 
recently. Its anti-inflammatory properties include the abihty to block IFNy release, 
inhibit the proliferation of Thl ceUs stimulated by macrophages decrease MHC class 
II expression on monocytes, block IL12 release by macrophages and down-regulate 
macrophage cell-surface expression of the co-stimulation hgand B7. However, ILIO 
has since been shown to be selective in its effects on ah APCs, thus limiting its 
applicability for blocking THl responses.
The dominant AFC in the ahoimmune response is the dendritic cell, and 
ILIO is unable to inhibit dendritic ceh activation of naive T ceUs (Macatonia et al.
31
1993). Prolonged administration of rILlO has been shown to have a detrimental 
effect on graft survival whereas a short peri-operative course of rILlO produced only 
marginally prolonged heart allograft survival in mice (Lowry et al, 1995). Although 
it has been shown to have an indirect effect on Thl regulation, ILIO seems to have 
either pro or anti-inflammatory effects on tolerance induction and this may be 
dependent on the nature of the APCs present and the local micro-environment.
IL4 has been classed as one of the two signature cytokines of Th2 cells, 
along with IL5 (Abbas et al, 1996), and its expression is closely associated with 
tolerance induction although whether its presence is necessary for, or a product of 
this process is still unclear. Its known that naive C D 4^ cells are activated by antigen 
and IL4 to express the Th2 phenotype which in turn can direct an allograft response 
away from a pro-inflammatory Thl response. Strom et al, (1996), postulated that 
the expression of Th2 cytokines in graft tolerising therapies is linked to an autocrine 
Th2 pattern caused by a sparse T cell infiltrate or IL4 expression. This ongoing IL4 
gene expression then polarises the Th2-type response and leads to long term 
engraftment by prevention of the Thl-type response. The administration of an anti- 
IL4 mAb at the time of treatment has been reported to abrogate the tolerising effects 
of a combined anti-CD4 mAb and DSBT regime, depending on the strain 
combination used. Strom et al, (1996), and Maeda et al, (1994), using a class II 
reactive C D 4^  cell clone, which produced IL4 and ILIO, but not IL2 and IFNy 
showed that it could inhibit antigen specific C D 8^ cell responses and prolong 
disparate skin graft survival.
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Several groups, however, have shown that the presence of IL4 may not be necessary 
for, and indeed may be detrimental to tolerance induction in some models. Fanslow 
et al, (1991), reported that the administration of soluble IL4R to neutralise IL4 led 
to allograft prolongation instead of the predicted acute rejection. Farges et al, 
(1995), carrying out rat liver transplants using both DA—>Lewis and Lewis^DA 
strain combinations found similar immune responses in both models except in the 
expression of IL4 mRNA. They noted that tolerance was associated with reduced 
levels of IL4, suggesting no shift to Th2. Morris et al, (1995), using a pig proislet 
xenograft transplantation model noted the activation of Th2 cells during rejection 
and a lack of IL4 expression during tolerance, but when tolerance was reversed, it 
was accompanied by an increase in IL4 mRNA expression.
Thus, although the application of various tolerising therapies in most cases 
switches a Thl to a Th2 type response, the expression of IL4 , in the absence or 
diminution of IL2 expression does not guarantee graft tolerance, and the failure to 
express IL2 may be more valuable than IL4 expression in tolerance induction (Strom 
et al, 1996).
1.6 Induction of tolerance to allografts
The clinical goal of transplantation is to induce specific tolerance to alloantigen thus 
negating the requirement of the long term use of immunosuppressive drugs . Several 
different hypotheses have been advanced to explain the development of tolerance, 
e.g. Clonal deletion, clonal anergy and suppression (Dallman, 1993). For many years, 
it was suspected that suppressor cells were the key factor in peripheral tolerance
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despite the fact that distinctive suppressor cells could not be identified. However, 
despite the findings of some groups that adoptively transferred cells firom tolerant 
animals into slightly immunosuppressed naive recipients could prevent the rejection 
of the subsequent graft (Dallman et al, 1993), the concept of tolerance by 
immunosuppression has not been widely accepted.
The clonal deletion of antigen specific T cells in the thymus was also 
proposed as a potential tolerance induction mechanism. Webb et al, (1990), showed 
that deletion of cells occurred in adult mis I*’ mice made tolerant of the 
superantigen m lsr expressing cells although the recipient mice had been 
thymectomised prior to tolerance induction, thus ensuring that no new T cells could 
reach the periphery. It was also shown that some immunosuppressive drugs e.g. 
CsA could enhance T cell deletion 3 or 4 fold in superantigen (mlsl^ and SEE) 
immunised mice (Vanier and Proud’homme, 1992). However, deletion alone cannot 
account for the fact that in euthymie tolerant animals, antigen specific T cell thymic 
emigrants are unresponsive to the tolerising antigen and are not deleted (Dallman et 
al, 1993). Of all the methods postulated to induce transplantation tolerance to 
allografts, clonal anergy has emerged as the forerunner. Induction of anergy or 
unresponsiveness in antigen specific T cells has been shown to be accompanied by an 
inability of the alloreactive T cell to produce IL2 or proliferate in spite of the 
presence of cell surface IL2R (Alard et al, 1993), but that this state of 
unresponsiveness could be reversed by the addition of exogenous IL2 (Dallman et al, 
1993). It is thought that T cell anergy results after antigenic stimulation via the TCR 
has occurred and is caused by a lack of or deficiency of costimulatory signals such as
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B7 or cytokines and, consequently, the anergic T cell cannot participate in the 
rejection process (Anderson and Brennan, 1995).
As the induction of tolerance to allografts would seem to involve the 
alteration of the cytokine miheu, a study of the cytokine profile in several methods 
used to induce tolerance, eg. DSBT, CsA, and Antibody therapy as well as in 
ongoing graft rejection by methods such as In-situ Hybridisation(ISH) and the 
Polymerase Chain Reaction(PCR) may help to elucidate the complex picture of 
tolerance induction.
1.7 Cyclosporin A
Cyclosporin A(CsA) is a cychc polypeptide consisting of 11 amino acids which can 
be extracted from two species of fiinghi, Trichoderma polyspomm  and 
Cylindrocarpon lucidium booth (Borel and Weisinger, 1979 & Wenger, 1983). Its 
efficacy as a powerful immunosuppressant in graft rejection was demonstrated in a 
variety of animal models whereby withdrawal of the drug after a short course of 
therapy did not inevitably lead to graft rejection of kidney allografts in rabbits (Green 
and Allison, 1978), or heart grafts in rats (White et al, 1980). The grafts survived 
long after the administrated cyclosporin had been metabohsed and excreted. It was 
introduced into clinical human transplantation in 1978 (Caine et al, 1978), but as 
well as the beneficial effects reported, some serious side-effects came to light, such 
as nephrotoxicity, lymphomas and patient susceptibility to infection.
Studies correlating the dose of cyclosporin administered and the 
immunosuppression of cardiac allograft rejection across various incompatible rat
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strains showed that a subtherapeutic dose (1.5mg/kg/day) was ineffectual, but that 
low therapeutic (3mg/kg/day), therapeutic (5mg/kg/day) and tolerogenic 
(lOmg/kg/day) 14 day dose schedules produced prolonged heart allograft survival 
(mean survival time(mst) > 100 days). The amount of immunosuppression 
corresponded to blood cyclosporin levels, with the therapeutic dose (5mg/kg/day) 
showing blood levels of >300ng/ml (Miyagawa et al, 1991). Serum levels lower than 
lOOng/ml have been found to be associated with rejection, whereas levels greater 
than 250ng/ml are associated with toxicity (Kahan et al, 1986).
Attempts to overcome the problems of cyclosporin toxicity, while still 
retaining graft survival resulted in several groups using lower doses of drug or 
shorter time scale regimes combined with administration of donor blood (Perloff and 
Baker, 1984), purified donor T cells (Oluwole et al, 1989), or extract of donor 
histocompatibility antigens (Didlake et al, 1988), with varying degrees of success. 
Others, e.g. Stepkowski et al, (1989), compared normal systemic delivery of 
subtherapeutic levels of the drug to osmotic pump delivery continuous infusion over 
14 days and found that animals under systemic treatment either by intra- 
peritoneal(I.P.) or oral gavage methods rejected their mismatched grafts in 8 days 
(mst) whereas direct local delivery of the cyclosporin showed increased graft 
survivals of 40 days (mst).
Although treatment with CsA prolongs graft survival, it doesn’t prevent 
leucocyte infiltration into the graft. Some groups e.g. Chisholm and Bevan, (1988), 
when analysing the kinetics and phenotypes of the cell infiltrate, showed that
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cyclosporin treated rats had substantially fewer infiltrating cells than rats undergoing 
acute rejection and that the specificity of these cells for alloantigen was also reduced 
Bradley et al, (1985), did not find such marked decrease in graft infiltrating cell 
numbers but did note that these cells could not effect any marked donor specific 
cytotoxicity. Ito et al, (1990), using limiting dilution analysis(LDA) showed a 
marked decrease in cytotoxic T cell reactivity to donor type target cells in CsA 
treated rats and that both CD4^ and C D 8^ cell subsets specifically suppressed the 
proliferative response of recipient T cells against donor stimulator cells in the mixed 
lymphocyte reaction(MLR). They postulated that administration of CsA was 
characterised by either inactivation or clonal deletion of effector cells.
Despite the abihty to induce immune unresponsiveness to solid organ 
allografts, it has also been shown that CsA can induce forms of autoimmunity. In 
rats, CsA can cause severe thymic medullary involution, categorised by a loss of 
medullary dendritic cells (Beschomer et al, 1987), causing partial thymocyte 
maturation arrest at the CD4^ CD8^ stage and the emigration of these immature 
thymocytes to the periphery and lymph nodes (Cherwoan and Goldschneider, 1991). 
This disruption of thymic mechanisms has been shown to inhibit the clonal deletion 
by apoptosis of self- MHC class II reactive cytolytic T cells and under certain 
conditions, induce a systemic autoimmune syndrome called syngeneic graft versus 
host disease(GVHD)(Gao et al, 1988). Studies by Zhang et al, (1995), have shown 
evidence that T cells bearing the TCR determinant vp8.5\ which mediate the acute 
phase of GVHD seemed to be preferentially expanded in the periphery and thymus 
and appear in the allograft during CsA treatment, but do not precipitate graft
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rejection. They hypothesised that these MHC class II autoreactive T ceUs may 
interact with alloreactive T cells causing a hyporesponsiveness to donor alloantigens 
and a partial peripheral clonal deletion of these cells,
1.7.1 Mode of action
The immunosuppression mediated by CsA involves the production , by activated T 
cells of cytokines including IFNy (Wiskocil et al, 1985), and IL2 (Elliot et al, 1984). 
In the cell, the CsA forms complexes with cyclophilin which then binds to and blocks 
the activity of calcineurin, a Ca^Vcalmodulin dependent protein phosphatase. This in 
turn activates a cytoplasmic component of NEAT(nuclear factor for activated T 
cells) which migrates to the nucleus and binds to another component and forms the 
active nuclear factor NFAT which is known to regulate the transcription of 
cytokines, including IL2 (Schreiber and Crabtree, 1992 & McCaffrey et al, 1993). 
This cascade of events inhibits activation, prohferation and function of effector cells.
These effects of CsA may alter the balance between the mutually 
antagonistic Thl (IL2 secreting) and Th2 (IL4 secreting) T cell subsets, for example, 
CsA has been shown to enhance DTH (Thl-dependent) type responses in mice 
(Behforouz et al 1986), but conversely, it sometimes promotes IgE (Th2-dependent) 
production (Chen et al, 1989). Th2 clones have also been reported to be more 
resistant to the action of CsA than Thl clones (Gajewski et al, 1990). The overall 
effect of CsA on tolerance seems to be influenced by many factors including dose, 
time of administration of the drug and the type of antigenic stimulation.
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1.8 Donor-specific blood transfusion
The importance of consanguinity in transplantation was noted in the 1930s, when 
skin grafts from one family member to another seemed to last longer than those from 
unrelated donors (Murray, 1992). Around the same time, the existence and 
importance of MHC antigens as transplantation barriers was being discovered in the 
mouse (Gorer, 1937), and was further defined by Snell, (1948). Billingham et al, 
(1953), experimentally went one stage further by showing that neonatal mice of one 
strain, that were injected with whole blood from a different strain could, when 
reaching adulthood, accept skin grafts from the immunising strain showing that 
donor specific tolerance could be achieved. Halasz et al, (1964), using a canine renal 
allograft model showed that subcutaneous injection of donor blood on days 10 and 5 
preoperatively significantly prolonged graft survival. In 1973, two different groups, 
both using human renal allograft models reported the beneficial effects of blood 
transfusion on graft survival. Newton and Anderson, (1973), used pre-transplant 
transfusion of donor lymphocytes under cover of azathioprine, a potent 
immunosuppressant, to achieve successful acceptance of the kidney graft. Opelz et 
al, (1973), also reported that preoperative blood transfusions improved graft survival 
and went on to show that 5 or more transfusions increased the survival of allografts 
by 20% compared to non-transfused recipients.
One of the major drawbacks of donor specific transfusions is recipient 
sensitisation to the organ donor, characterised by the development of allospecific 
cytotoxic antibodies which can cause early graft rejection. The use of various 
immunosuppressive drugs, e.g. cyclosporin during the blood transfusion protocol
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successfully limited the chances of sensitisation occurring, without losing the 
beneficial effects of the transfusion (Cheigh et al, 1991). However, the combination 
of possible donor sensitisation, repeated blood transfusions and the possible 
transmission of potentially hazardous viral infections, together with the excellent 
results obtained using immunosuppressive drugs, e.g. cyclosporin, prednisone and 
azathioprine either alone or in combination has caused most transplant centres to 
abandon donor-specific transfusions in living related transplants in favour of the drug 
regimens.
The importance of MHC antigens as transplantation barriers was 
investigated in experiments using congenic mice and rats. The results showed that 
shared class I or II MHC antigens alone, between donor and recipient, was sufficient 
to produce graft enhancement, but sharing of both class I or class II MHC was 
necessary for maximal effect on graft survival (Soulillou et al, 1984), while Madsen 
et al, (1988), using a mouse cardiac allograft model clearly demonstrated that by 
pretreating recipients with syngeneic cells that had been transfected with class I or 
class II MHC genes, graft survival could be prolonged.
The roles of blood cell components in allograft enhancement has been 
studied by several groups, and it has been shown that in a Lewis-^DA renal allograft 
model, recipient treatment with enriched B cells, which express both class I and class 
II MHC antigens results in indefinite graft survival, as does pre-treatment with T 
cells (CD4‘^ and CD8^) and C D 4^ cells alone (both class II expressors) whereas
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C D 8 ^  cells (class I expressors) were totally ineffective (Cranston et al, 1987 & 
Olewole et al, 1989).
Groups studying graft infiltrating cells have shown that, compared to grafts 
in non-transfused recipients, blood transfused rats have a more rapid leucocyte 
infiltration on day 3 post-transplant, but by day 5, both enhanced and rejecting grafts 
showed similar levels. Accelerated induction of donor class I and class II MHC has 
also been noted in enhanced grafts, thought to be caused by cytokines, e.g. IFNy 
released by the activated infiltrating T cells (Wood et al, 1988). The levels of donor- 
specific cytotoxicity, produced by graft infiltrating cells and splenocytes in vitro are 
broadly similar in enhanced and rejecting graft recipients, although a decrease in 
C D 8 ^  cells and IL2R positive cells has been noted in enhanced grafts, whereas 
C D 4 ^  cell numbers remained similar (Armstrong et al, 1987). Dallman et al, (1989,
1991) found that blood transfusion-induced tolerance was accompanied by 
diminished IL2-dependent T cell proliferation, and that the tolerising effect of donor 
blood transfusion could be reversed by administration in vivo of exogenous 
recombinant IL2(rIL2). As there was no reduction in recipient cytotoxicity against 
donor cells in vitro, it seemed likely that tolerance induction was not due to clonal 
deletion of alloreactive T cells.
A number of groups studying the CD4^ Th dichotomy in allograft rejection 
and enhancement found that in rejection, Thl-like cells dominate whereas in 
tolerance induced by DSBT, Th2-like cells producing IL4 and ILIO persisted in 
grafts and spleens, suggesting that tolerance to alloantigen was caused by
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preferential activation of Th2 cells which could suppress Thl cells (Takeuchi et al,
1992). Josien et al, (1995), analysing C D 4^ cells CD45RC phenotype, which in rats 
mimics the Thl/Th2 dichotomy seen in mice and humans, found that there were less 
CD45RC*”^*’ (Thl-like) cells present in DSBT recipient grafts on day 5 post­
transplant compared to untreated recipients. Interestingly, although CD45RC °"^  cells 
predominated in DSBT grafts, and showed similar levels in untreated recipients, 
there was an underexpression of both Thl and Th2-like cytokine mRNA levels, as 
detected by PCR analysis, in DSBT recipients compared to untreated ones. It was 
thus postulated that this deficiency of T cell helper function caused reduced levels of 
antidonor IgG and IgM antibodies noted by other groups (Downie et al, 1990).
In general, graft survival in DSBT seems to depend on various factors, e.g. 
time and volume of blood transfusion, the strain combinations of animals used and 
the type of graft, with heart and kidney grafts reportedly benefiting from the 
transfusion effect compared to skin and pancreas (Perloff and Barker, 1984 & Fabre 
and Morris, 1972). The transfusion protocol itself can be critical to graft survival, 
e.g. the duration of time between transfusion and transplant can cause either 
sensitisation if too short or diminished beneficial effects if too long (Fabre and 
Morris, 1972).
1.9 Anti-CD4
The CD4 antigen is expressed on mature peripheral T cells and immature thymocytes 
in rats, mice and humans (Reinherz and Schlossman, 1980). It is also expressed by 
monocytes, macrophages and Langerhans cells in man (Wood et al, 1983), and tissue
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macrophages in rats, but not mice (Crocker et al, 1987). CD4 acts as an accessory 
molecule by binding to class II MHC molecules on APCs and contributes to class II 
restriction for antigen recognition by the aP TCR of C D 4^ cells, leading to T cell 
activation (Janeway, 1989), and upregulation of IL2R expression (Johnson and 
Eichmann, 1990).
CD4 is a transmembrane glycoprotein which has a molecular weight of 55 
kD and a cytoplasmic portion which has a 79% amino acid sequence homology 
between humans and rodents. The cytoplasmic tail is 40 amino acids long with 29 of 
the first 32 residues identical in humans and mice, and this fact led some groups to 
suggest that it was involved in signal transduction (Littman, 1987), while Veillette et 
al, (1988), demonstrated that CD4 was non-covalently associated with the protein 
tyrosine kinase p56*‘^‘‘ which was known to be pivotal in intracellular signalling events 
culminating in T cell activation.
As the C D 4^ cell subset has been shown to be the main initiator of 
rejection of organ allografts, targeting immunosuppressive therapy to T cells 
expressing this molecule was seen to be an obvious method of abrogating graft 
rejection.
Monoclonal antibodies(mAbs), directed against the CD4 surface molecule 
were first given to cynomolgus monkey renal allograft recipients (Cosimi et al, 1981) 
while Cobbold et al, (1984), showed that mice conditioned with anti-CD4 mAbs 
could tolerate their skin allografts. They have also been shown to suppress antibody 
responses against soluble antigens (Benjamin and Waldmann, 1986), block the
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development of autoimmune disease (Shizuru et al, 1988), and allow permanent 
acceptance of allogeneic islets of langerhans in diabetic mice, if given pre-transplant 
(Shizuru et al, 1987).
The timing of the administration of the antibody, in relation to antigenic 
challenge has been shown to be important. The inhibitory effect of anti-CD4 
antibody was shown to be maximal if the interaction with its receptor occurred prior 
to stimulation of the TCR/CD3 complex (Nel et al, 1990). Sablinski et al, (1991), 
using BWH-4, a mouse anti-rat CD4 antibody, given to naive recipients of cardiac 
allografts as a low dose, 7 day pre-transplant regimen showed that the grafts were 
maintained indefinitely compared to the same regimen given for 7 days post­
transplant which was barely effective. This was followed up with a similar set of 
experiments using sensitised recipients. Graft survival in the sensitised recipients 
was maximal when anti-CD4 mAb was administered prior to the sensitising skin 
graft (21  days), intermediate when given between skin graft and heart graft (c. 12 
days) but minimal if given at the time of transplant (Sablinski et al, 1991). However, 
Bishop et al, (1994) using a mouse cardiac transplantation model gave the C57B1/6 
recipients a low dose of GK 1.5, a rat anti-mouse CD4 mAb one day before and after 
transplantation of DBA/2 hearts and reported a 56% survival rate 60 days post- 
operatively whereas RIB5/2, a mouse anti-rat CD4 mAh, when given daily from one 
day pre to day 3 post-transplant and then twice weekly for five weeks to 
BDIX(RT1^'^') rat recipients of Wistar-Furth(RTr) donor kidneys, led to permanent 
graft survival in 50% of the rats (Siegling et al, 1993). The common factor in both
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sets of experiments however was that the first antibody load was given prior to 
transplantation.
Many groups have studied whether the elimination of target cells is 
required to achieve anti-CD4 mAb mediated immunosuppression. Darby et al, 
(1992), compared the mode of action of a panel of six rat anti-mouse anti-CD4 
mAbs of varying epitope specificities and different isotypes with their ability to 
deplete C D 4^  cells in vivo, and found that antibodies of the IgG2b isotype caused 
profound depletion of C D 4^ cells whereas IgG2a antibodies caused only partial 
depletion, but also noted that the use of either depleting or non-depleting antibodies 
could bring about indefinite graft survival.
Cellular clearance of C D 4^ cells by anti-CD4 mAbs has been linked to 
different isotypes used (Waldmann, 1989) and it was postulated that cells are deleted 
by opsonisition caused by membrane bound C3b acting as a hgand for C3b receptors 
on macrophages and granulocytes (Darby et al, 1992). Bishop et al, (1991), using 
the depleting GK 1.5 antibody in a mouse heart transplant model studied the 
phenotypes of mononuclear graft infiltrating ceUs and showed that at day 6 post­
transplant in rejecting hearts, 20% of the infiltrate was CD4 positive whereas in the 
GK1.5 treated animals, only 2% or less of the infiltrate were CD4 positive and this 
decreased to virtually nil by day 21 post-transplant, C D 8^ ceh numbers did not 
differ in rejecting or antibody treated animals. Mottram et al, (1995), using the same 
depleting GK 1.5 antibody showed that splenic C D 4^ cells had been depleted to 
<1% on days 7 and 14 post-transplant but that the heart allografts were stih able to
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survive indefinitely. The percentage of C D 4^ cells had recovered somewhat by day 
21 post-transplant and the mice did not reject donor-type skin grafts at day 30 post­
transplant, but rapidly rejected third party skin, thereby showing alloantigen specific 
tolerance.
Shizuru et al, (1990), likewise, using 0X38, a mouse anti-rat CD4 
antibody of isotype IgG2a, showed that its administration selectively depleted 80- 
95% of C D 4^ cells and that 75% of the treated recipient ACI(RTr) rat strain 
maintained their donor Lewis(RTl’) grafts indefinitely, accepted second donor strain 
hearts, but rejected third party ones. However, although long term ACI recipients 
were unresponsive to Lewis hearts in vivo, in vitro, their cellular responses against 
Lewis spleen cells in MLR experiments were similar to those of untreated control 
rats, while the experiments of Mottram et al, (1995), showed that cells from GK 1.5 
treated animals caused a profound lack of growth and response to alloantigen in 
MLR. Also, long-term cell lines could not be grown from cells isolated from GK 1.5 
treated hearts despite the addition of alloantigen, mitogen ( concanavilin A) and 
growth factors to the medium.
Sablinski et al, (1991), and Shizuru et al, (1990), both postulated that the 
divergent effects of antibody treatment reported were caused by several factors 
including the dose of antibody used and the treatment regimens, epitope specificity 
of the antibody, whether the antibody was depleting or non-depleting or whether low 
or high responder animal strains are used as graft recipients. Yin and Fathman, 
(1995), using low responder ACfrRTF) and high responder Lewis(RTl^) rats as both
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donors and recipients of heart and kidney allografts studied the role of 0X38 mouse 
anti-rat CD4 mAh, administered on days 3 , 2 , 1  and 0 pre-operatively in prevention 
of graft rejection. They showed that in the low responder ACI rats, donor-specific 
tolerance of both hearts and kidneys was achieved by the anti-CD4 therapy whereas 
in the high responder Lewis rats, kidneys, but not hearts were tolerated. They also 
showed that kidney allograft tolerance in the high responders could induce tolerance 
to donor-matched allogeneic hearts grafted at day 100 post-transplant and found that 
the conflicting results between high and low responders correlated with a more 
profound and longer lasting depletion of CD4^T cells in the low responders.
Evidence collated from many groups studying cytokine and receptor 
profiles in anti-CD4 mAh treated animals has shown a marked decrease in IL2R 
expression (Sablinski et al, 1991 & Mottram et al, 1995), and the virtual ablation of 
Thl-like cytokines IL2 and IFNy and preservation of the Th2-like cytokine IL4, 
compared with rejecting models (Siegling et al, 1993, Mottram et al, 1995, Hancock 
et al, 1992 & Papp et al, 1992).
It has been postulated that this scenario may be brought about by the 
administered antibody coating the CD4 molecule, thus reducing the amount of 
CD4/MHC class II interaction sites and stimulating Th2-like cells which require a 
lower number of TCR/CD4 complexes to be triggered than Thl-like cells, in this 
way disturbing the Thl/Th2 cell balance in favour of Th2 whose cytokines, when 
released, can cause suppression of Thl cells leading to preservation of the allograft 
(Siegling et al, 1993 & Kupiec-Weglinski et al, 1993).
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1.10 In-Situ Hybridisation
In-situ hybridisation(ISH) techniques allow specific nucleic acid sequences to be 
detected by relying on base-pairing (G-C and A-T) between endogenous target RNA 
or DNA sequences and a labelled complimentary probe sequence in tissues whose 
morphology has been preserved. The technique was originally developed in 1969 for 
localising specific DNA sequences on chromosomes (Pardue and Gall, 1969), and 
since then, the methodology has been gradually modified to allow the exact cellular 
location of specific RNAs and DNAs in tissue sections or single cell preparations to 
be pinpointed with relative accuracy unlike other hybridisation methods such as 
Northern Blot analysis which can only confirm the presence or absence of specific 
RNA species in an organ or heterogeneous cell population (Thomas, 1980). This 
thesis explores the use of ISH in transplanted tissues with the aim of visuahsing the 
distribution and frequency, within the graft, of leucocytes expressing mRNA for 
certain cytokines which seem to play important roles in mediating rejection of , or 
maintaining tolerance to, transplanted tissues. ISH as a method is a very individual 
procedure, and has to be optimised and developed depending on various parameters, 
including the size of the target molecule, copy numbers of target molecule available 
for hybridisation to, types of tissue to be used and alterations to that tissue (e.g. 
fibrosis etc.) depending on whether the graft is rejecting or tolerant.
1.10.1 Probes
Initial ISH studies used mainly double-stranded complimentary DNA probes (Lloyd 
and Landefeld, 1986), which were synthesised by either nick translation or random
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priming and had to be denatured before use, or, single stranded complimentary RNA 
probes, also known as Riboprobes (Hoeffler et al, 1986),whose synthesis involves 
linearisation by a restriction enzyme of a plasmid into which a probe sequence has 
been cloned, and transcription of sequences downstream of the appropriate initiation 
site by a purified RNA polymerase.
1.10.2 Probe labels
Riboprobes and DNA probes were usually labelled by the enzymatic addition of a 
radioisotope of choice, e.g. Tritium(^H), Phosphorus(^^P), Iodine(*^^I) or 
Sulphur(^^S) and detected by autoradiography. Although these methods were highly 
sensitive, several disadvantages in their use became obvious, including the very long 
exposure times required by low-energy isotopes (^H), limited spatial resolution 
problems with high-energy isotopes (^^P), the potential health hazards and safety 
measures required and the limited shelf-hfe of short half-life isotopes (Larsson, 
1989). However, some of the major obstacles were removed by the modification of 
these nucleic acid probes by the introduction of non-radioactive labels.
Two types of non-radioactive labelling exist. The Direct method, whereby 
the detector(reporter) molecule e.g. fluorescein is directly incorporated into the 
probe, and is visualised immediately after hybridisation with no need for 
immunocytochemistry to visualise the signal (Dirks et al, 1991), or the Indirect 
method, where the similarly incorporated reporter molecule is detected by affinity 
cytochemistry. Two of the main reporter molecules used are biotin and digoxigenin.
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Biotin
This is a member of the vitamin B complex and was developed as a reporter 
molecule by Langer et al, (1981). It has since been very widely used and is detected 
by anti-biotin antibodies or more usually by streptavidin which has a higher binding 
capacity. However, a major drawback to the use of biotin is that certain tissues 
including liver and kidney contain high endogenous biotin levels which can cause 
serious problems with background staining.
Digoxigenin
The digoxigenin system, developed by Boehringer Mannheim Ltd, does not have this 
problem as its only natural source is the digitahs plant from which the steroid is 
extracted and, consequently, should not cause any background staining. Like biotin, 
it is incorporated enzymatically into nucleic acid probes and is detected with high- 
affinity antibodies, usually conjugated to alkaline phosphatase.
1.10.3 Oligonucleotides
The advent of synthetic oligonucleotides as probes (Oligoprobes) resulted in 
significant improvements in ISH methodology. These are synthesised from known 
nucleic acid sequences and their design and construction either in-house or 
commercially does not need access to cloned genes and significantly reduces probe 
production times.
Oligos are typically made in sizes from 15->45mers, substantially smaller 
than either DNA or Riboprobes. They are usually end-labelled during their
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construction and have the advantage that several oligos, complimentary to different 
regions of the same mRNA target sequence can be manufactured and mixed in equal 
proportions in a hybridisation reaction, thus attaching more label onto target 
sequences. Their smaU size is also advantageous, allowing them to diffuse through 
the dense cellular matrix which may surround target sequences more easily than 
larger probes (Lewis et al, 1985).
1.10.4 Hybridisation
Each stage of the hybridisation method, from the tissue preparation at the outset, 
through the conditions used to obtain specific hybridisation, to the end-stage 
visualisation of the specific signal has to be carefully optimised.
Morphology preservation
To ensure preservation of tissue morphology, the arrestment of any potentially 
degrading enzymes and the preservation and immobilisation of target mRNA 
sequences, the tissues must be fixed as soon as possible, either pre-paraffin 
embedment or post-cryostat sectioning, depending on the system utilised. Different 
tissues require different fixatives, e.g. acetone (Farquharson et al, 1992), and 
paraformaldehyde and neutral buffered formalin (Farquharson et al, 1990). Many of 
these fixatives cross-link proteins and this can mask the target nucleic acid sequence, 
so permeabilisation of the tissue by acids, detergents and/or enzymes is sometimes 
necessary to enable probe access to the target sequence. If proteinases are used, the 
correct concentrations have to be titrated to avoid over-digestion of the tissue and 
loss of target sequence (Larsson, 1989).
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Non-specific binding
Many parameters have to be considered when calculating the optimal conditions for 
hybridisation . Some groups use a pre-hybridisation step to block non-specific 
binding of probe to non-complimentary sequences or basic proteins. This usually 
involves an incubation with the basic hybridisation solution minus the probe, but 
which contains non-complimentary sequences such as yeast tRNA, salmon sperm 
DNA or calf thymus DNA, and denhardts solution to ensure the blockage of 
hydrogen bonding to basic proteins. Although blocking is necessary, it has been 
shown that the presence of these agents in the hybridisation solution alone is 
adequate thereby removing the need for a pre-hybridisation step altogether (Ogilvie 
et al, 1990).
Hybridisation
Various hybridisation times have been used, although most groups find it more 
convenient to hybridise overnight using low probe concentrations, instead of using 
shorter times and higher concentrations (Larsson, 1989) which may lead to increased 
background staining. The hybridisation temperature used depends on the melting 
temperature (Tm) of the hybrids formed. The Tm is the temperature at which 50% of 
the hybrids dissociate, therefore, any hybridisation temperature used must be below 
this. The Tm in turn is dependent on several factors, i.e. the higher the monovalent 
cation concentration and G-C base pair frequency, the higher the Tm value. Probe 
length is also a factor, with longer probes forming more stable hybrids. Depending
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on the type of probe used, the addition of formamide is sometimes called upon to 
allow lower hybridisation temperatures to be used, thus avoiding any morphological 
deterioration that can occur to the tissues used above 50-55®C (Larsson, 1989). 
Many groups, especially those using oligoprobes have, however, found that the 
addition of formamide to the hybridisation solution has led to unwanted background 
staining and, consequently, its use to be not beneficial to the method (Larsson, 1989 
& Farquharson et al, 1992).
Post-hybridisation
During hybridisation, hybrids form between perfectly and imperfectly matched 
sequences. To dissociate the latter and thus reduce background staining, a series of 
washes of varying stringencies are usually utilised. The higher the temperature and 
the lower the salt concentration used, the more stringent the wash, and this is usually 
carried out up to a few degrees below the calculated Tm of the hybrids. Some 
groups however have reported that washes at the hybridisation temperature, 
followed by washes at room temperature are sufficient and that high stringency 
washes actually decreased signal detection (Bentley and Singer, 1985).
Detection
Most non-isotopic detection systems, e.g. the alkaline phosphatase conjugated anti- 
digoxigenin antibody system, necessitate that incubation with a substrate is necessary 
to form an insoluble coloured product. However, the enzymes used in such systems 
may themselves be endogenously present in the tissue of study, therefore they may 
have to be inactivated in order to avoid confusion with possible specific signal. In the
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case of alkaline phosphatase, it has been shown that the addition of levamisole to the 
substrate solution is adequate as a precaution although generally, most endogenous 
enzymatic activity should be lost during the course of the different hybridisation 
method stages (Murray et al, 1992).
1.11 Polymerase chain reaction
The Polymerase Chain Reaction(PCR) is a technique that has been developed to 
amplify specific DNA sequences of interest efficiently in vitro, even when the 
starting amounts of material are extremely small. PGR was used in this thesis to 
determine the presence, in transplanted tissues, of leucocytes synthesising mRNA for 
certain cytokines. It was important to establish, by PGR, the presence of a particular 
cytokine in a particular tissue in order to develop the optimal reaction conditions for 
the detection of that cytokine by In-situ hybridisation.
The principle of PGR was first described in detail by Kleppe et al, (1971), 
and the methodology devised and named by Saiki, Erlich and Mullis at the Getus 
corporation (Saiki et al, 1985). Early PGR procedures were tedious and laborious 
and usually involved moving tubes between water baths of varying temperatures and 
keeping a close count on the number of reaction cycles completed. Nowadays, the 
procedure is virtually fully automated, and involves a PGR thermal cycler in which 
cycle numbers, incubation times and heating block temperatures are frilly 
programmable, allowing specific standardisation for each different DNA species 
being amplified.
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1.11.1 Reaction requirements
There are several basic requirements for the reaction template, primers, buffer 
containing magnesium, DNA polymerase and four deoxyribonucleoside 
triphosphates(dNTPs).
Complimentary DNA(cDNA) is commonly used as a template due to its 
ease of synthesis from mRNA using an oligo d(T) primer and an RNA-dependent, 
DNA polymerase called Reverse Transcriptase in the presence of an excess of 
dNTPs at 37^C. Two oligonucleotide primers, commonly 15->25mers, each 
complimentary to opposite strands of the DNA sequence of interest and oriented 
with their 3' ends towards each other anneal at specific temperatures to the 
complimentary DNA strands which have been denatured at 90-95°C to separate 
them. Primer sequences should have similar G-C content, minimal secondary 
stmcture and low complimentarity to each other, particularly in the 3' region. The 
tract of DNA, lying specifically between the two primers is then preferentially 
amplified at a specific expansion temperature in the presence of magnesium buffer 
and large molar excesses of dNTPs and a DNA polymerase.
Originally, the enzyme of favour was the large fragment DNA polymerase 
derived from Escherichia coli(E coli) known as the Klenow fragment. However, this 
had the major drawback of having to be added after each dénaturation stage due to 
its instability at high temperatures. The enzyme Taq polymerase extracted from the 
heat-loving bacterium Thermus aquaticus is now widely used as it is stable and
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active even at the high temperatures associated with dénaturation, and does not have 
to be added to the reaction mixture at each cycle.
1.11.2 Efficiency and specificity
The standardised cycles featuring dénaturation, annealing and extension 
temperatures and times can be repeated ad infinitum, and specific DNA accumulates 
exponentially until one component of the reaction mixture becomes exhausted. 25 to 
40 cycles are usually sufficient for optimum amplification although this may vary 
depending on the amount of starting material available and the efficiency of each 
amplification step. The use of ‘nested primers’ has been shown to be very effective at 
improving amplification efficiency. This involves the use of a pair of oligo primers 
designed to anneal to sequences internal to the original primers. Only a small amount 
of the original amplification product is needed, along with fresh enzyme, buffer, 
dNTPs etc. A further set of amplifications is then performed, providing additional 
specificity to the reaction and dramatic increases in the amount of amphfication 
product (Bell, 1989).
1.11.3 Visualisation of product
The end product of this type of reaction is double-stranded DNA fragments of a 
defined length which can then be visualised, usually by electrophoretic migration on 
an agarose gel which is consequently stained with fluorescent nucleic acid binders 
such as ethidium bromide, and observed under ultra-violet transillumination. 
Appropriate molecular weight markers of known size are commonly included in each 
gel run and used to compare and verify product band size, which should be visible as 
a sharp band. Small DNA products, and sometimes primers themselves can appear as
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diffuse bands near the leading front of the gel, and if extra bands appear, these may 
be due to the presence of single-stranded product which can occur if the primers are 
used at unequal concentrations.
1.12 Aims
The aims of this thesis were primarily to develop and utilise an ISH method capable 
of relating the potential for specific cytokine production (i.e. cytokine message) to 
patterns of distribution and frequency of graft infiltrating cells in both rejecting heart 
grafts and heart grafts from recipients rendered tolerant by antibody, blood 
transfusion and drug regimens. To ensure that relevant infiltrating cells were present 
in the allografts, morphometric analysis of the infiltrate using specific monoclonal 
antibodies was carried out, followed by PCR analysis to establish the presence or 
absence of particular cytokine mRNA transcripts in the tissue being analysed. As 
PCR can only detect the presence of cytokine message but cannot relate this 
message to pattern of cellular infiltrate (focal or diffuse), or to individual cells, an 
ISH method was developed to see if any pattern of association could be detected 
between cell infiltration and the expression of certain cytokines known to have a 
mediating role in organ transplantation.
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Chapter 2
Materials and Methods
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2.1 Animals
Inbred male Lewis(RTl') and DA(RXr''^) rats were obtained from Harlan UK 
Ltd(Bicester, Oxon, UK), and maintained under normal temperature conditions with 
free access to food and water in the animal facility of the University of Glasgow. All 
animals used for transplantation were 8 - 1 0  weeks old.
2.2 Surgical procedures
2.2.1 Cardiac transplantation
All microsurgical procedures were carried out as described by Ono and Lindsey, 
(1969). Under inhalation anaesthesia (2% halothane in oxygen), Lewis donor hearts 
were transplanted heterotopically into the abdomens of DA recipients with the donor 
aorta and pulmonary artery being anastomosed to recipient abdominal aorta and vena 
cava respectively. Lewis hearts were also transplanted into other Lewis rats as 
controls. On completion of anastomoses, the clamps were removed and haemostasis 
achieved using Surgicel (Johnson and Johnson Pharmaceutical, UK). Cold ischaemic 
times were never more than 30 minutes and heartbeats were monitored daily by 
palpation of the abdomen. Rejection was defined as cessation of palpable myocardial 
contraction.
2.3 Perioperative treatments
2.3.1 Cyclosporin A
Cyclosporin A (Sandoz Pharmaceuticals, Leeds, UK), was prepared as a lOmg/ml 
solution in pure olive oil by heating at 70°C for 1-2 hours with continual stirring. 
A dose of 15mgs/kg was administered to DA recipients by oral gavage on days 0 
(transplant) and days 1,2,3 post-transplant.
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2.3.2 Donor-specific blood transfusion
1ml of fresh heparinised donor Lewis blood was administered to DA recipients by 
injection into the dorsal penile vein, 7 days prior to transplantation.
2.3.3 Preparation and purification of MRC 0X38 monoclonal antibody 
Hybridoma cells, secreting 0X38 (A gift from Dr. Barclay, MRC Cellular 
Immunology unit. Sir William Dunn school of Pathology, Oxford, UK), were 
injected intra-peritoneally into Balb/c mice which had been pristane-primed 2 weeks 
previously.
Ascitic fluid was harvested from the peritoneal cavity between 10 days and 
5 weeks post injection and centrifuged at 3,000rpm(2000 x g) at 4°C for 15 minutes. 
The supernatant was passed through a 0.2pm paradise 25 disposable filter (Whatman 
Int., Maidstone, Kent, UK), and an equal volume of IM glycine dilution buffer pH
8 . 6  ( see appendix), was added before being left overnight at 4°C. Next morning,
the sample was passed through a protein-A-sepharose column (Prosep 
A)(Bioprocessing Ltd, Durham, UK), which had been equilibrated with IM glycine 
binding buffer pH 8 . 6  (see appendix) at a flow rate of 10 mls/min. As Prosep A has a 
high affinity for the Fc portion of IgG, O.IM citrate buffer pH 3 (see appendix), was 
used to elute the IgG (including 0X38 which is of the IgG2a subclass).
A UV-1 single-path monitor (Pharmacia Ltd, St. Albans, UK), was used to 
measure the optical density of the eluate at 280nm and a Frac-100 fraction collector 
(Pharmacia Ltd, UK), was programmed to collect peak fractions containing IgG 
which were subsequently pooled and dialysed for 72 hours at room temperature 
against several changes of phosphate buffered saline (PBS).
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The IgG2a was quantified by assay on a Radial Immunodiffusion (RID) 
plate (Binding site Ltd, Birmingham, UK), against a known standard (calibrator). 
The test sample was diluted with bovine semm albumin (BSA) (Sigma Ltd, Poole, 
Dorset, UK), and 5pi added to the plate which contained monospecific antiserum in 
agarose. When the diameter of the calibrator had reached 9mm in a minimum 
diffusion time of 96 hours for IgG2a, callipers were used to measure the ring 
diameter of the test sample, and the concentration calculated from the RID reference 
table supplied.
2.3.4 0X38 Monoclonal antibody therapy
DA recipients were given lOmgs/kg 0X38 in PBS intra-peritoneally 3 days prior to 
transplantation and 3 subsequent doses of 2mgs/kg each, 2 days, 1 day and shortly 
before transplantation.
2.4 Excision, preparation and storage of tissue
Recipient rats were sacrificed by cervical dislocation and hearts immediately excised 
and bisected. One half, to be used for PCR was immediately wrapped in aluminium 
foil and snap-frozen in hquid nitrogen (B.O.C Cryospeed, Glasgow, UK). The 
remainder, to be used for Histology and ISH was placed in an aluminium foil mould, 
covered with Tissue-Tek O.C.T embedding medium (BDH Ltd, Lewes, Sussex, 
UK), and immediately snap-frozen in liqid nitrogen. All tissue was stored at -70°C 
until use.
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2.5 Histology
2.5.1 Antibodies
A panel of mouse monoclonal antibodies (Serotec Ltd, Oxford, UK), were used to 
detect various rat leucocyte antigens (Figure 1.1). Peroxidase conjugated rabbit anti­
mouse Ig (Dako Ltd, High Wycombe,UK) was used to detect primary monoclonal 
antibody.
2.5.2 Gélatinisation of slides
Multispot slides (C.A Hendley, Essex, UK), were washed for 30 minutes in 2% 
Decon 90 (Decon Labs,Hove, UK), rinsed in running tap water and placed in a fresh 
solution of 0.5% gelatine, 0.125% chrome alum (BDH, UK), in deionised water for 
15 minutes at room temperature before being left to air-dry overnight.
2.5.3 Cryostat sections
5pm sections were cut at -lOPC on a cryostat (Slee Corp., UK), and placed on the 
gelatinised slides which were then allowed to air-dry for 30 minutes.
2.5.4 Indirect Immunoperoxidase staining
The air-dried sections were fixed in acetone for 10 minutes at room temperature, air- 
dried for 45 minutes and re-hydrated in PBS. 50pl of diluted primary antibody was 
placed on each section which was then incubated for 45 minutes at room 
temperature in a humidified box before being washed three times in PBS to remove 
unbound antibody. The area around each section was carefully dried with tissue prior 
to the addition of 50pl of a 1/40 dilution of peroxidase conjugated rabbit anti-mouse 
Ig containing 10% normal rat semm (to avoid cross-reaction) for 30 minutes at
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Designation Specificity References
MRC 0X1 
MRC 0X8
EDI
MRC 0X39
R73
W3/25
Common Leucocyte Antigen 
CD8 ^  cells, some NK cells
Macrophages, Dendritic cells
IL2Ra
apTCR
Sunderland et al, 1979
Barclay, 1981 
Dallman et al, 1982 
Cantrell et al, 1982
Dijkstra et al, 1983
Patterson et al, 1987
Hunig et al, 1989
C D 4^ cells, some Macrophages Brideau et al, 1980
Barclay, 1981
Figure 1.1 Mouse monoclonal antibodies to Rat leucocyte antigens
The panel of antibodies listed above were all purchased from Serotec Ltd UK and 
were used to detect various rat leucocyte antigens by the indirect immunoperoxidase 
method on frozen sections of tissue from rejecting and tolerised rat heart allografts 
as detailed in 2.5—>2.5.5.
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room temperature in a humidified box. After further washes in PBS, the peroxidase 
substrate 3, 3 diaminobenzidine tetrahydrochloride at a concentration of 0.6mgs/ml 
containing 0.01% hydrogen peroxide ( both Sigma,UK), was added to each slide. 
When a noticeable colour change had occurred, the excess substrate was removed, 
and the slides washed in miming tap water before being lightly counterstained in 
Harris haematoxlylin (BDH, UK), dehydrated through increasing concentrations of 
absolute alcohol, placed in two changes of fresh xylene and mounted in DPX 
mounting medium (both BDH, UK).
2.5.5 Morphometric analysis of graft infiltrate
A Leitz Dialux 22BB microscope was used to examine each section and 
morphometric analysis carried out by counting the number of positively labelled cells 
in each of ten high power fields per section. Each slide was examined at a 
magnification of 200 with the aid of an eyepiece graticule using a Nikon Optiphot 
microscope which also allowed photographs to be taken. Statistical analysis was then 
carried out, and the results plotted on graphs. Random sections were also examined 
by an independent observer to validate the results.
2.6 In-situ Hybridisation
2.6.1 Specific probes
Anti-sense oligonucleotide probes (Figure 1.2), specific for rat IL2 and IL4 mRNA 
target sequences were computer designed, chemically synthesised, and modified by 
the addition of digoxigenin molecules at both 5' and 3' ends before being purified by 
HPLC(high pressure liquid chromatography) by R&D Systems, Abingdon, UK. Each 
probe consisted of a cocktail of three 30mer, equimolar(0.2|iM), exon specific
64
IL2
Sequence
5' TGAGCATCATGGGGAGTTTCAGATTCTTGTA 3'
5' ATCTCCTCAGAAATTCCACCACAGTTGCTG 3'
5' CATTGTTGAGATGATGCTTTGACAGATGGCT 3'
A cocktail of the above 3 rat antisense IL2 oligonucleotide probes (two 31 mers and 
one 30mer) was made by mixing equimolar amounts of each probe for use in 
experiments detailed in 2.6.6 and 2.6.9. Probe cocktail Tm value = 77.5°C.
Probe 1
Probe 2
Probe 3
IL4
Sequence
Probe 1 5'
Probe 2 5'
Probe 3 5'
A cocktail of the above 3 rat antisense IL4 oligonucleotide probes (three 30mers) 
was made by mixing equimolar amounts of each probe for use in experiments 
detailed in 2.6.6 and 2.6.9. Probe cocktail Tm value = 79.5°C.
Figure 1.2 In-situ Hybridisation probes
All probes were supplied by R&D Systems Ltd UK and were categorised by the 
addition of digoxigenin molecules at both 5" and 3' ends. Tm values were calculated 
by the % G-C content method. The probes were used to hybridise with specific 
target mRNA sequences in tissue sections of rejecting and tolerised rat heart 
allografts as detailed in 2.6—>2.6.1 1 .
65
probes with closely matched Tm values (IL2—77.5®C, IL4—79.5®C)(both by %G-C 
content). A cocktail of six equimolar, digoxigenin labelled human Insulin 30mer 
oligonucleotide probes (R&D Systems, UK), was used as a negative hybridisation 
control and a digoxigenin labelled poly d(T) probe used as a positive control.
2.6.2 Preparation of poly d(T) probe
This oligonucleotide probe which specifically binds to poly A tails of mRNA 
molecules was made by mixing 4jil of 5x terminal transferase buffer, 2pl of ImM 
digoxigenin-11-dUTP, 2\i\ of 1 mg/ml pd(T)2o, 2|il of 20,000U/ml terminal 
deoxytransferase (all Promega Ltd, Southampton, UK), and lOpl of 
diethylpyrocarbonate(DEPC) (Sigma Ltd, UK), treated H2O (see appendix) in an 
eppendorf tube and incubating for two hours in a 37®C water bath. The labelled 
probe was purified by passing through a NAP-5 column (Pharmacia, UK), containing 
DNA-grade Sephadex G-25 which had been pre-equilibrated with 10 mis of a 0.1% 
sodium dodecyl sulphate(SDS), 0.1% saline sodium citrate(SSC) solution (see 
appendix). Probe was eluted from the column by the addition of 2mls of the 
SDS/SSC solution and collecting ten 200pl fractions of eluent, of which 5pl of each 
fraction was removed and subsequently dotted onto Hybond N^ nucleic acid transfer 
membrane (Amersham Int., Little Chalfont, UK), and left to air-dry before being 
placed in a 37°C incubator overnight to stabilise the probe onto the membrane.
Next day, the membrane was re-hydrated in tris-HCL pH 7.5 buffer (see appendix) 
for ten minutes at room temperature, placed in 1% Blocking agent (BDH, UK), in 
tris-HCl pH 7.5 buffer for one hour, rinsed in tris buffer again briefly before the 
addition of alkaline phosphatase conjugated anti-digoxigenin antibody (BDH, UK),
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diluted 1/5000(150mU/ml) in tris buffer pH 7.5 containing 1% normal sheep semm 
(to reduce non-specific binding).
Unbound antibody was removed by several washes in tris buffer pH 7.5, 
and after a ten minute wash in tris-HCl buffer pH 9.5 (see appendix), black spots, 
characteristic of positive probe labelling were visualised by the addition of a 
substrate solution containing 175|li1 of 5-bromo-4-chloro-3-indolyl phosphate(BCIP) 
and 225\il nitro blue tetrazolium(NBT) (both Sigma, UK), in tris buffer pH 9.5. 
Fractions corresponding to the two darkest spots were pooled together and freeze 
dried. The resulting pellet was resuspended in 30|xl of DEPC treated H2O and was 
then ready for use.
2.6.3 Silane treated slides
Superfrost slides (Shandon Ltd, Runcorn, UK), were washed in 2% Decon 90 
(Decon, UK), for thirty minutes, rinsed in mnning tap water, placed in a solution of 
2% APES(3 aminopropyltriethoxysilane)(Sigma, UK), in acetone for ten minutes at 
room temperature and rinsed briefly in mnning tap water and allowed to air-dry prior 
to use.
2.6.4 Cell lines
Two Chinese hamster ovary(CHO) cell lines (from Dr. Barclay, MRC Cellular 
Immunology unit. Sir William Dunn school of Pathology, Oxford), transfected with 
rat IL2 and IL4 genes were used as hybridisation targets to test probe specificity.
2.6.5 Medium
Both cell lines were maintained in GMEM(Glasgow modification of Eagles medium), 
containing 5% heat inactivated foetal calf semm(FCS), 2mM L-glutamine, lOOIU/ml
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penicillin, lOOpgs/ml streptomycin (all Gibco BRL, Paisley, UK), and 25|xM Special 
salt mixture(Advanced Protein Products, Brierly Hill, UK), in 75mm^ tissue culture 
flasks (Gibco, UK), in a 5% CO2 incubator.
2.6.6 Hybridisation of cell monolayers
When cell lines were confluent, the medium was removed, the cells were washed 
with Mg^^, Ca^ "^  -free hanks balanced salt solution(HBSS)(Gibco,UK), and 3mls of 
trypsin/EDTA solution (Flow Labs, Irvine, UK), added to the flask to remove 
adherent cells which were then transferred to 1 0ml sterile plastic centrifuge tubes 
and spun at 1200rpm for ten minutes at room temperature. The subsequent pellets 
were washed three times in HBSS, and cell numbers and viability checked using an 
improved Neubauer Haemocytometer. The cell concentration was adjusted to 
2xl0Vml and lOOpl, = 2x10^ cells, transferred to a Shandon cytocentrifuge and spun 
at SOOrpm for eight minutes, producing monolayers of cells spotted onto APES 
coated slides.
These were immediately fixed in 4% paraformaldehyde (Sigma, UK), in 
PBS for twenty minutes at room temperature. After subsequent washes in PBS, 
protein cross-linking, caused by fixation was partially digested by the addition of 
IfXg/ml proteinase K solution (Sigma, UK), for fifteen minutes at 37°C, allowing 
probes access to target sequences. Further PBS washes were followed by a five 
minute re-fix in 4% paraformaldehyde/PBS to retain cellular integrity, and several 
more PBS washes to remove fixative before the tissue was dehydrated by two 
minute washes in increasing(50^75->95->100%) concentrations of absolute 
alcohol and left to air-dry for one hour.
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The cells were hybridised with 40jil of hybridisation buffer (see appendix), 
containing various probe concentrations, (0 .1->lng/|il), or hybridisation buffer alone 
as control, at 37®C overnight in a sealed, moist chamber, lined with tissue soaked in 
4xSSC solution.
2.6.7 Detection
Next morning, the slides were washed in decreasing concentrations of SSC solution, 
i.e. two 30 minute washes in 2xSSC, and two 30 minute washes in IxSSC, all at 
room temperature, followed by two 30 minute washes in O.lxSSC in a shaking water 
bath at 45°C which was slightly below the Tm of the probes calculated for that 
specific salt concentration, to remove unhybridised and non-specifically hybridised 
probe. After a brief five minute wash in tris-HCl pH 7.5 buffer (see appendix), the 
samples were blocked for one hour with 5% normal sheep semm in tris pH 7.5 
buffer at room temperature. lOOpl of 1.5mU/ml alkaline phosphatase conjugated 
anti-digoxigenin antibody containing 0.3% Triton X-100 (Sigma, UK), and 3% 
normal sheep semm was added for two hours at room temperature. Unbound 
antibody was then removed by washing several times in tris pH 7.5 buffer.
After a brief wash in tris pH 9.5 buffer, the slides were immersed in 
substrate solution containing BCIP and NBT as before (see 2.6.2) in Tris pH 9.5 
buffer, but with the addition of 0.24mgs/ml levamisole (Sigma, UK), to inhibit any 
endogenous alkaline phosphatase activity. Colour development was checked 
periodically using a Nikon Optiphot microscope, and when deemed adequate, the 
samples were rinsed in mnning tap water for thirty minutes and mounted in 
Glycergel (Dako, UK).
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2.6.8 Cryostat sections
5|im sections were cut at -lOPC on the Slee cryostat, placed on APES treated 
microscope slides and kept at -20°C until fixation.
2.6.9 Hybridisation of tissue sections
The samples were removed from the cryostat and immediately fixed in a 4% 
paraformaldehyde/PBS solution for twenty minutes at room temperature before 
being washed several times in PBS, dehydrated through increasing absolute alcohol 
concentrations (as in 2.6.6) and air-dried for one hour at room temperature. Sections 
were hybridised overnight at 37°C with 40fxl of hybridisation buffer (see appendix) 
containing various concentrations of specific probe (0.1->lng/fxl), poly d(T) probe 
as positive control, or hybridisation buffer alone as negative control, in a sealed 
moist chamber as before (see 2 .6 .6 ).
2.6.10 Detection
Next morning, decreasing SSC concentration washes, blocking, antibody, and 
substrate stages were carried out essentially as described as before (see 2.6.7) with 
the exception of the positive control poly d(T) probe which, due to its nature is not 
as strongly bound to its target sequences ( poly A tails of all mRNA sequences) as 
the specific probes are to theirs. It was therefore washed twice in 2xSSC for 30 
minutes followed by one wash in IxSSC for 15 minutes all at room temperature.
2.6.11 Photography
A Nikon Optiphot microscope with Nikon camera attachment was used to take 
photographs, using Kodak Ektachrome 64T colour reversal film (Kodak Ltd, UK), 
of the relevant slides.
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2.7 Polymerase chain reaction analysis of cytokine cDNAs
2.7.1 RNA extraction
300mgs of frozen heart tissue was homogenised in 3mls of trizol reagent (Gibco, 
UK), and incubated for five minutes at room temperature to permit complete 
dissociation of nucleoprotein complexes. Two 1ml fractions of debris-free 
homogenate were placed in sterile 1.5ml eppendorf tubes, and 200|il of chloroform 
added. The samples were briefly vortexed, incubated at room temperature for three 
minutes, and centrifuged at 12,(X)0xg at 4®C for fifteen minutes.
600|xl of the upper aqueous phase was transferred to fresh sterile tubes and 
600|xl of Isopropanol added to precipitate the RNA at room temperature for ten 
minutes. The samples were centrifuged again at 12,000xg at 4°C for fifteen minutes 
and supernatants carefully removed. 1ml of 75% ethanol was added to wash the 
pellet, and the samples were re-centrifuged at 7,500xg at 4°C for five minutes. The 
supernatants were again carefully removed, and the pellets dissolved in 40|xl of 
DEPC/H2O.
The purity and concentration of each sample was determined by taking 
optical density (OD) measurements at 260 and 280nm on a spectrophotometer. An 
OD of 1 at 260nm= 40|Xgs/ml RNA and a OD 260/280 ratio of 1.6—>2.0 shows good 
RNA purity.
2.7.2 cDNA preparation
lOpgs of total RNA in 24pl was primed by the addition of 2pl of 0.5pgs/ml 
oligo(dT) 12-18 primer (Gibco, UK), and placed in a PCR 480 Thermal Cycler (Perkin 
Elmer Ltd, Beaconsfield, UK), which had been pre-optimised for cDNA preparation.
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The pre-optimised cycle consisted of the samples being incubated at 70^C for ten 
minutes and cooled to 4°C for five minutes, after which lOpl of 5x reverse 
transcriptase buffer, 4|il of O.IM dithiothreitol and 2|li1 of lOmM dNTP mix (all 
BDH, UK), were added by careful mixing, after which the samples were incubated 
for a further two minutes at 37°C before the addition of 2|il of 200U/|xl Superscript 
RNAse H reverse transcriptase (BDH, UK). The mixture was re-incubated at 37°C 
for one hour followed by five minutes at 90®C, before being removed and stored at 
4®C short-term or -20^C for longer periods.
2.7.3 Amplification of specific cDNAs
Before use, all alcohol swabbed pipettes and racks, all sterile pipette tips, tubes, and 
DEPC/H2O were placed adjacent to an ultra-violet light source for thirty minutes, 
rendering any contaminating DNA present unamplifiable.
A Gene-Amp 9600 DNA Thermal Cycler (Perkin Elmer, UK), was used to 
amplify Ijxl of cDNA in a 25\i\ reaction volume containing 0.4|xl of lOmM dNTP 
mix (BDH, UK), 0.75|il of 50mM MgCb, 2.5pl of lOx PGR buffer, O.l^il of SU/pl 
Tag DNA polymerase (all Gibco, UK), 2.5|xl of each sense (0.1 pM) and anti-sense 
(0.1 pM) primers (Cruachem Ltd, Glasgow, UK),(Figure 1.3), and sterile distilled 
water. For the specific amplification of IL4, 1.25pl of 50mM MgClz was used, with 
a corresponding decrease in the volume of sterile water.
Pre-optimised programmes for IL2 and IL4, consisting of a five minute 
incubation at 94°C, followed by 36 cycles for IL2 or 41 cycles for IL4 were used. 
Each cycle consisted of dénaturation at 94®C, primer annealing at 60°C and 
polymerisation at 72®C, all for thirty seconds each, and samples removed at 3 cycle
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Primer Sense Sequence Tm
pA ctin  (+) 5' ATGCCATCCTGCGTCTGGACCTGGC 3' 82“C
(-) 5' AGCATTTGCGGTGCACGATGGAGGG 3' 80®C
Reference:- Nudel et al, 1983 Product size 607 base pairs
IL2 (+) 5' CATGTACAGCATGCAGCTCGCATCC 3' 78°C
(-) 5' CCACCACAGTTGCTGGCTCATCATC 3' 78®C
Reference:- M^Knight, et al 1989 Product size 409 base pairs
IL4 (+) 5' TGATGGGTCTCAGCCCCCACCTTGC 3' 82°C
(-) 5' CTTTCAGTGTTGTGAGCGTGGACTC 3' 76°C
Reference:- M^Knight et al, 1991 Product size 377 base pairs
Figure 1.3 PCR primers
All the above 25mer oligonucleotide primers were purchased from Cruachem Ltd 
UK and were used in the amplification of specific cDNA sequences that had been 
extracted from rejecting and tolerised heart allografts as detailed in 2.7—>2.7.4. (+) 
and (-) refer to sense and anti-sense sequences respectively.
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intervals (at cycles 24,27,30,33 and 36 for IL2, and at cycles 29,32,35,38 and 41 for 
IL4), for gel electrophoresis.
Two negative controls were included with each reaction. These consisted 
of reaction mixtures minus primers and cDNA respectively.
A PCR reaction for P actin, to confirm RNA extraction and cDNA viability 
was carried out. Concentrations and volumes were similar to the IL2 amplification 
except that the final primer concentration was 0.1 pM. Three cDNA concentrations; 
neat, 1/10 and 1/100 were amplified as before for 25 cycles, with the samples being 
removed after 15,20 and 25 cycles for gel electrophoresis.
2.7.4 Gel electrophoresis
15pl of PCR product was mixed with 4pl of loading buffer (see appendix), loaded 
onto a 1.5% agarose gel (see appendix), and run at 125v for one and a half hours on 
a Hybaid gel apparatus (Hybaid Ltd, Teddington, UK), using 5x TBE as running 
buffer (see appendix). 3pl of a DNA molecular weight marker (BDH, UK), 12pl of 
DEPC/H2O and 4pl of loading buffer were mixed and run on every gel as a positive 
control and to confirm product size.
The gels were subsequently stained with 5pl of lOmgs/ml ethidium 
bromide (Sigma, UK), in lOOmls of 0.5x TBE buffer for one hour. PCR product 
bands were then visualised using a UV Transilluminator and semi-quantitive analysis 
carried out on each gel by noting the presence or absence of specific bands, and 
comparing the number and intensity of the ethidium bromide stained bands where 
applicable.
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Chapter 3
Phenotypic analysis of infiltrating cells 
in reiecting and tolerant rat 
heart allografts
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3.1. Introduction
One of the hallmarks of allograft rejection is the presence of a progressive 
heterogeneous mononuclear cell graft infiltrate containing mostly macrophages and 
CD4+ and CD8 "T cells (M'Whinnie et al, 1985).
This leads to an increase in donor class I and class II MHC antigen 
expression within the graft caused chiefly by cytokines, e.g. IFNy released by 
activated infiltrate cells and inevitably leads to loss of graft function and its ultimate 
destruction (Armstrong et al, 1987). The pattern of allograft infiltration by these 
donor specific cells has been studied by many groups. Bishop et al, (1992) showed 
that the number of C D 4^ cells remained constant throughout the rejection episode, 
whereas conversely, the same group described a progressive rise of these cells 
peaking at the time of rejection (Bishop et al, 1991). CD8 ^  cells on the other hand 
have been shown to be barely detectable at day 3 post-transplant but to increase 
rapidly by day 5, overtaking C D 4^ cell levels, and to level off, increase or diminish 
during the final events of graft rejection depending the animal models used (Bishop 
et al, 1991, Bishop et al, 1992 & Armstrong et al, 1987).
The accumulation of graft infiltrating cells in animals rendered tolerant by 
either CsA, DSBT or anti-CD4 monoclonal antibody therapies has also been closely 
studied. Bradley et al, (1985), found that cyclosporin A treated rats had similar levels 
of infiltrate to rejecting rats whereas Chisholm and Bevan, (1988), noted a marked 
decrease in graft infiltrating cell numbers in the CsA treated rats compared to those 
undergoing rejection, although both agreed that these cells couldn’t effect any 
donor-specific cytotoxicity.
76
The use of DSBT to achieve tolerance has been shown to accelerate 
cellular infiltration into the graft by day 3 post-transplant as well as increasing the 
induction of donor class I and class II MHC antigens, while the levels of alloantigen- 
specific cytotoxicity have been shown to be similar in comparison with rejecting 
grafts (Dallman et al, 1987 & Armstrong et al, 1987).
The analysis of donor alloantigen-specific T cell presence in the allografts 
of recipients treated with anti-CD4 mAh has been carried out by several groups, with 
the added interest here being that the C D 4^ cell itself is being directly targeted. The 
administration of GK 1.5, a depleting anti-mouse CD4 mAh perioperatively has 
been shown to deplete intragraft C D 4^ cell population to as httle as 1-2 % by day 6  
post-transplant (Bishop et al, 1991 & Mottram et al, 1995), or even to make their 
levels undetectable (Bishop et al, 1992). Interestingly, while there is a general 
consensus regarding intragraft C D 4^ cell depletion levels, the observed effect of 
this treatment on intragraft CD8 ^  cell numbers is more controversial. A drop by > 
98% in intragraft CD8 ^  cell numbers on day 6  post-transplant has been noted 
(Bishop et al, 1993 & Bishop et al, 1992), although Mottram et al, (1995), using a 
different monoclonal antibody regimen found no diminuation of CD8 ^  cells at all.
Taking these findings into account it was therefore of interest to compare 
and contrast the phenotypes and kinetics of the graft infiltrating cells at different time 
stages during acute rejection and during CsA, DSBT and anti-CD4 mAh tolerance 
induction regimens.
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3.2 Analysis of graft infiltrating cells
Rejecting Lewis heart grafts from unmodified DA recipients and non-rejecting grafts 
from DA recipients tolerised by DSBT, CsA and anti-CD4 regimens were analysed 
for leucocyte infiltration.
Allografts from rejecting and anti-CD4 treated recipients were excised on 
days 2, 5 and 7 post-transplant whereas control syngeneic, DSBT and CsA treated 
grafts were taken at day 5 only. Cryostat sections were made of each sample and 
these were labelled with a panel of monoclonal antibodies, specific for rat leucocyte 
antigens (see Figure 1.1) using the indirect immunoperoxidase staining method. 
Morphometric analysis of each labelled section was then carried out by counting the 
number of positively labelled cells in each of 1 0  high power fields per section using a 
microscope. Each slide was examined at a magnification of 200 using a microscope 
eyepiece graticule in situ.
Means and standard deviations were calculated for each phenotype 
studied, and graphs of the results plotted. Day 7 rejecting grafts showed significant 
tissue damage and thus it was not always possible to count 10 high power fields. The 
morphometric analysis was carried out by the author, and random tissue sections 
were also analysed by an unbiased observer (Dr.S.E.Middleton) to verify the 
findings.
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3.2.1 0X1
The MRC 0X1 antibody, which binds to the common leucocyte antigen was used to 
measure the total leucocyte infiltration into the graft. The results are shown in 
Figures 2.1 and 2.2.
Infiltration by 0X1 positive cells occurred more rapidly in anti-CD4 treated 
recipient grafts than in rejecting ones ( day 2 post-transplant 102±18 versus(vs) 35±9 
labelled cells per high power field). By day 5 post-transplant, both rejecting and anti- 
CD4 tolerised grafts showed large increases in infiltrate numbers with the tolerised 
grafts having nearly double the amount of 0X1 positive cells than rejecting grafts 
(171±18 vs. 90+14). However, by day 7, the number of positive cells in rejecting 
grafts had increased by nearly two-fold (90±14 vs. 165±38) compared to day 5 
rejecting whereas in the anti-CD4 treated animals, day 7 numbers had dropped to 
131+36 from the high of 171118 on day 5 and the rejecting grafts now had more 
leucocyte infiltrate than the anti-CD4 treated grafts (165138 vs. 131136). This was 
accompanied by severe myocyte damage to the heart tissue which was not evident in 
the antibody treated group. Day 5 0X1 positive cell levels in both DSBT and CsA 
treated recipients were higher than the rejecting grafts but lower than the antibody 
treated grafts, and all groups tested were significantly higher than the syngeneic 
control grafts.
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Figure 2.1 Morphometric analysis of 0X1 positive cell infiltrate in 
Rejecting and Tolerised Lewis Heart Allografts in DA recipients.
Lewis grafts were removed on different days after transplantation from 
Rejecting(n=4), DSBT(n=2), Cyclosporin A(n=2) and 0X38 Anti-CD4 
treated recipients(n=4). Cryostat sections were labelled with 0X1 antibody 
(against the leucocyte common antigen) using the indirect
immunoperoxidase method, and the number of positive cells/ high power 
field was determined. Syngeneic Lewis heart grafts were stained as a 
control. The results are expressed as the mean and standard deviation of 
cells in 10 high power fields.
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4Figure 2.2 0X1 labelling of a Lewis Heart Allograft from an 0X38 Anti-CD4 
treated DA recipient at Day 5 post transplant. (x200)
Ciyostat sections of Lewis heaits were labelled with 0X1 antibody (labels Leucocyte 
Common Antigen) using the Indirect Immunoperoxidase method. Sections 
counterstained with Haematoxylin.
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3.2.2 0X8
The MRC 0X8 antibody was used to stain C D 8^ cells and some natural killer (NK) 
cells, and the results can be seen in Figures 2.3 and 2.4.
On day 2 post-transplant, the number of 0X8 positive cells in the rejecting 
grafts was barely discernible compared to those in the anti-CD4 treated animals (2±2 
vs. 2713) although by day 5, there had been a large influx of C D 8 ^  cells in both 
rejecting and anti-CD4 treated grafts and there was still a significantly higher number 
in the anti-CD4 grafts. The levels of 0X8 positive cells in syngeneic and CsA treated 
grafts on day 5 were very low, although DSBT grafts had a higher number of 
positive cells than the rejecting grafts (4918 vs. 3214). On day 7 however, in anti- 
CD4 treated grafts, the number of 0X8 positive cells more than halved (75110 vs. 
3314) while rejecting grafts showed only a small diminution in numbers and were 
now broadly comparable with the antibody treated grafts (2716 vs. 3314)
3.2.3 EDI
EDI monoclonal antibody was used to label graft infiltrating cells of the 
monocyte/macrophage phenotype. The results are shown in Figure 2.5.
On day 2 post-transplant, EDI positive cells were nearly four times more 
common in anti-CD4 treated grafts than in rejecting ones (77117 vs. 2017), roughly 
mirroring the 0X1 results. By day 5, EDI positive cells in the rejecting grafts 
increased dramatically from day 2 (68118 vs. 2017) and was now at a similar level to
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Figure 2.3 Morphometric analysis of 0X8 positive cell infiltrate in 
Rejecting and Tolerised Lewis Heart Allografts in DA recipients.
Lewis grafts were removed on different days after transplantation from 
Rejecting(n=4), DSBT(n=2), Cyclosporin A(n=2) and 0X38 Anti-CD4 
treated recipients(n=4). Cryostat sections were labelled with 0X8 antibody 
(against CD8 positive cytotoxic T cells and some NK cells) using the 
indirect immunoperoxidase method, and the number of positive cells/ high 
power field was determined. Syngeneic Lewis heart grafts were stained as 
a control. The results are expressed as the mean and standard deviation 
of cells in 10 high power fields.
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Figure 2.4 0X 8 labelling of a Lewis Heart Allograft from an 0X38 Anti-CD4 
treated DA recipient at Day 5 post transplant. (x200)
Cryostat sections of Lewis hearts were labelled with 0X 8 antibody (labels Cytotoxic 
T cells and some NK cells) using the Indirect Immunoperoxidase method. Sections 
counterstained with Haematoxylin.
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Figure 2.5 Morphometric analysis of ED1 positive cell infiltrate in 
Rejecting and Tolerised Lewis Heart Allografts in DA recipients.
Lewis grafts were removed on different days after transplantation from 
Rejecting(n=4), DSBT(n=2), Cyclosporin A(n=2) and 0X38 Anti-CD4 
treated recipients(n=4). Cryostat sections were labelled with ED1 antibody 
(against monocytes/macrophages) using the indirect immunoperoxidase 
method, and the number of positive cells/high power field was 
determined. Syngeneic Lewis heart grafts were stained as a control. The 
results are expressed as the mean and standard deviation of cells in 10 
high power fields.
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the antibody treated grafts. DSBT and CsA treated grafts also contained a large 
influx of cells on day 5 (63+9 vs. 50125 respectively), but was still lower than both 
antibody treated and rejecting grafts which by day 7 post-transplant showed further 
increases in EDI positive cells (8018 vs. 93119 respectively).
3.2.4 W3/25
As can be seen in Figures 2.6 and 2.7, there was a steady progressive increase in 
W3/25 positive infiltrating cells (C D 4^ helper cells and some macrophages) from 
day 2 to day 7 in rejecting allografts (1916 vs. 82119), whereas in the anti-CD4 
treated grafts, although the level of positive cells was higher than in rejecting grafts 
on day 2, the figure was barely half that of the rejecting grafts (3814 vs. 82119). On 
day 5, aU grafts except the syngeneic control grafts contained more W3/25 positive 
cells than in the anti-CD4 treated grafts.( It should be noted that the W3/25 antibody 
binds to an epitope on the CD4 molecule which is different from that bound by the 
0X38 anti-CD4 mAh used for tolerance induction.
3.2.5 0X39
MRC 0X39 antibody was used to label the a  chain of the IL2R which is upregulated 
during T cell activation. The results can be seen in Figures 2.8 and 2.9.
There was a massive increase from barely perceptible levels on day 2 post­
transplant to day 5 (111 vs. 35114) in rejecting grafts although by day 7, the 
numbers fell again, albeit only slightly. Anti-CD4 treated recipients had twenty times 
more 0X39 positive cells than rejecting grafts on day 2 and although there was a 
slight rise on day 5 post-transplant, the numbers fell back again on day 7 and showed
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Figure 2.6 Morphometric analysis of W3/25 positive cell infiltrate in 
Rejecting and Tolerant Lewis Heart Allografts in DA recipients.
Lewis grafts were removed on different days after transplantation from 
Rejecting(n=4), DSBT(n=2), Cyclosporin A(n=2) and 0X38 Anti-CD4 
treated recipients(n=4). Cryostat sections were labelled with W3/25 
antibody (against CD4 positive T helper cells and some macrophages) 
using the indirect immunoperoxidase method, and the number of positive 
cells/ high power field was determined. Syngeneic Lewis heart grafts were 
stained as a control. The results are expressed as the mean and standard 
deviation of cells in 10 high power fields.
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Figure 2.7 W3/25 labelling of a Rejecting Lewis Heart Allograft from a DA 
recipient at Day 7 post transplant. (x200)
Cryostat sections of Lewis hearts were labelled with the W3/25 antibody (labels CD4 
T helper cells and some Macrophages) using the Indirect Immunoperoxidase 
method. Sections counterstained with Haematoxylin.
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Figure 2.8 Morphometric analysis of 0X39 positive cell infiltrate in 
Rejecting and Tolerised Lewis Heart Allografts in DA recipients.
Lewis grafts were removed on different days after transplantation from 
Rejecting(n=4), DSBT(n=2), Cyclosporin A(n=2) and 0X38 Anti-CD4 
treated recipients(n=4). Cryostat sections were labelled with 0X39 
antibody (against IL2 Receptor alpha chain) using the indirect 
immunoperoxidase method, and the number of positive cells/ high power 
field was determined. Syngeneic Lewis heart grafts were stained as a 
control. The results are expressed as the mean and standard deviation of 
cells in 10 high power fields.
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Figure 2.9 0X39 labelling of botb Rejecting and Cyclosporin A induced
Tolerant Lewis Heart Allografts from DA recipients at Day 5 post transplant.
(x200)
Cryostat sections of Lewis hearts were labelled with 0X 39 antibody (labels IL2R 
alpha chain) using the Indirect Immunoperoxidase method. Sections counterstained 
with Haematoxylin.
a) Top - Rejecting Lewis heart.
b) Bottom - Cyclosporin A induced Tolerant Lewis heart.
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barely half the levels of IL2R positive cells than rejecting grafts. Levels in control 
syngeneic and CsA treated recipients on day 5 were very low (0.4+0.5 and 1.4+1 
respectively) whereas DSBT treated recipients grafts were somewhat higher, but still 
only half the anti-CD4 levels (12+4 vs. 23+4).
3.2.6 R73
The R73 monoclonal antibody was used to label the a^TCR positive infiltrating cells 
and as can be seen in Figure 2.10, from day 2 to day 7, there was an increase from 
virtually undetectable levels (2+1), to 70+14 in the rejecting grafts. Anti-CD4 treated 
recipients grafts also showed a progressive rise to higher levels by day 7 (82±4) 
albeit from a higher starting level on day 2 (23±3) compared to the rejecting graft 
(2+1). The highest level detected of all three different time points was in the DSBT 
treated recipient grafts (83+24) although the error margins were somewhat higher.
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Figure 2.10 Morphometric analysis of R73 positive cell infiltrate in 
Rejecting and Tolerised Lewis Heart Allografts in DA recipients.
Lewis grafts were removed on different days after transplantation from 
Rejecting(n=4), DSBT(n=2), Cyclosporin A (n=2) and 0X38 Anti-CD4 
treated recipients(n=4). Cryostat sections were labelled with R73 antibody 
(against alpha/beta T cell Receptor) using the indirect immunoperoxidase 
method, and the number of positive cells/ high power field was determined. 
Syngeneic Lewis heart grafts were stained as a control. The results are 
expressed as the mean and standard deviation of cells in 10 high power 
fields.
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3.3 Discussion
From these results, it can be noted that rejecting Lewis heart allografts from DA 
recipients were characterised by a progressive heterogeneous mononuclear cell 
infiltrate categorised by the presence of 0X1 positive cells that peaked shortly before 
graft rejection on day 7 post-transplant. Interestingly, graft recipients treated 
pre-operatively with a tolerising regimen of the non-depleting anti-CD4 0X38 mAb 
showed a more rapid cellular infiltrate into the graft, although by day 7, infiltrate 
levels were not as high as in the rejecting grafts. Similar results were reported by 
Armstrong et al, (1987) using DSBT as the tolerising regimen. On day 5 post­
transplant, both DSBT and CsA treated recipients, like anti-CD4 ones, showed 
elevated infiltrate levels compared to rejecting grafts and syngeneic controls.
A detailed study of the phenotypic differences of the graft infiltrate showed 
that in unmodified cardiac allograft recipients, the rejection process can be 
characterised by the intragraft presence of an increasing number of activated C D 4 ^  
helper cells (W3/25+ve) and CD8^ cytotoxic T cells (OX8+ve), and that this 
correlated with a concurrent rise in IL2R (OX39+ve) expression which peaked at the 
time of rejection. The presence of large numbers of EDI positive macrophages, 
again peaking at the time of rejection, and by then, being the more numerous 
phenotype present, allied with the drop in 0X8 positive cytotoxic T cells suggests 
that rejection in this series of experiments may be brought about by a DTH-like 
response caused by the large numbers of activated W3/25 positive, 0X39 positive T 
helper cells producing Thl type cytokines IL2 and IFNy, which in turn can stimulate
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the EDI positive macrophages to destroy the graft using the various lytic pathways 
at their disposal.
Irrespective of the more rapid influx of leucocytes in the anti-CD4 treated 
grafts compared to rejecting ones, it can be seen that by day 5 and day 7 post­
transplant, the number of C D 4^ cells, as characterised by the non-competing W3/25 
mAh was much lower in these tolerant grafts. This was to be expected as the non­
depleting 0X38 mAh used as tolerogen is directed at the CD4 molecule itself. The 
coating of the CD4 molecule by the antibody and subsequent reduction of 
CD4/MHC class II interaction sites, aUied with the decreasing amounts of IL2R 
positive cells may cause a reduction in Thl type cytokines IL2 and IFNy which are 
usually associated with rejection episodes, thus pushing the TH1/TH2 balance 
towards a Th2 like environment, which has been reported by some groups e.g. 
Siegling et al (1993) to be beneficial to graft preservation.
The day 5 results of both DSBT and CsA treated recipients show that like 
anti-CD4 treated recipients, leucocyte infiltration is more rapid than in rejecting 
grafts. Both show similar levels of macrophage infiltration to rejecting grafts but the 
CsA treated grafts show less CD8^ cytotoxic T cell levels and DL2R positive cells 
than any other group other than the syngeneic controls, although the number of 
C D 4 ^  cells is comparable with rejecting grafts. This distinct lack of IL2R positive 
cells has been noted by several groups, e.g. Padberg et al, (1988) and 
Hancock et al, (1990), and this, accompanied by this the disruption of IL2 
production, which is a hallmark of CsA administration and the decreased donor-
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specific cytotoxicity that can occur (Bradley et al, 1985) may contribute to the 
generation of Th2-like environment which may help to maintain the tolerant state.
The DSBT maintained grafts at day 5 also showed very low IL2R 
expression along with lower C D 4^ cell levels compared to rejecting grafts. This 
lack of IL2R expression in DSBT treated recipient grafts has been noted by other 
groups. Armstrong et al, (1987) reported that although C D 8^ cell infiltration was as 
a consequence diminished, donor-specific cytotoxicity was broadly similar to 
rejecting grafts in vitro. Others, e.g. Josien et al, (1995), also noted that C D 4 ^  cell 
levels were reduced in DSBT treated grafts compared to rejecting ones and 
postulated that this brought about reduced alloantibody levels and donor-specific 
tolerance. Since equivalent levels of donor-specific cytotoxic T cell lysis are found in 
both rejecting and DSBT treated allografts, it is improbable that clonal deletion of 
alloreactive T cells is the mechanism responsible for the induction and maintenance 
of tolerance. The reduced number of cells expressing IL2R, in spite of an equivalent 
cellular infiltrate would suggest, rather, that a state of tolerance is induced and 
maintained by the activation and persistence of Th2 cells, as suggested by Takeuchi 
et al, (1992) using similar models.
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Chapter 4
Application of the Polymerase Chain 
Reaction method to detect the presence 
of specific cytokines in reiecting and 
tolerant rat heart allograft tissue extracts
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4.1 Introduction
The application of the polymerase chain reaction(PCR) technique in the detection of 
specific mRNA sequences in both homogenised tissues and cell suspensions has been 
shown to be extremely useful when limited amounts of starting material are available 
(Wu et al, 1992), and allows very low levels of DNA expression (in theory as httle as 
a single molecule) to be amplified to levels easily detectable by conventional methods 
such as gel electrophoresis (Krams et al, 1992). PCR was used in this thesis to 
determine the presence or absence of specific cytokine (IL2 and IL4) mRNA 
sequences in rejecting and tolerised rat heart allografts prior to the use of in-situ 
hybridisation(ISH) techniques which, although not as sensitive as the PCR method, 
can pinpoint specific cells expressing the cytokine mRNA sequences, which PCR 
cannot.
To verify the integrity of the RNA extracted from the heart tissue and of 
the reverse transcription reaction itself, a preliminary PCR for p actin, which is 
expressed in various isoforms in nearly all eukaryotic cells was carried out on each 
sample to confirm the presence of PCR detectable cDNA. Negative controls in 
which primers and cDNA had been omitted from the reaction mixture, and positive 
controls comprising known PCR positive cDNA samples of the cytokines to be 
amplified were included in each reaction. Pre-optimisation of the technique for the 
cytokines under study and p Actin had been previously undertaken in our 
laboratories and showed that with the exception of primer concentrations, IL2 and P 
actin needed similar reaction mixture concentrations, whereas IL4 needed a higher
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magnesium concentration for maximum efficiency as well as slightly higher cycle 
numbers to maximise amplification.
The resulting PCR product was then analysed by gel electrophoresis in 
which a fraction of the reaction product, as well as a marker DNA ladder of known 
molecular weight band sizes was loaded onto a 1.5% agarose gel which was then run 
at 125v. When the band front had reached an appropriate distance, the gel was 
removed from the tank and stained with ethidium bromide which enabled the product 
bands to be visualised by ultra-violet transillumination. The product size was then 
verified against the appropriate DNA ladder marker bands, as was the appearance 
and absence of positive and negative control bands respectively.
4.2 Results
Hearts were harvested on days 2, 5 and 7 post-transplant from both rejecting and 
0X38 anti-CD4 treated rats (each n = 4), whereas CsA and DSBT treated hearts 
were only available on day 5 (each n = 2). They were immediately wrapped in tinfoil 
and snap frozen in hquid nitrogen. Ten micrograms(|Lig) of extracted total RNA was 
taken from each sample and reverse transcribed into cDNA. A p actin amphfication 
was carried out to confirm the integrity of the mRNA using three different 
concentrations of cDNA (neat, 1/10, 1/100). Cytokine specific primer pairs were 
then used to amplify neat cDNA which was derived from equivalent amounts of the 
extracted RNA. The products of each reaction were then analysed by gel 
electrophoresis and ethidium bromide staining. Photographs were then obtained 
under UV transillumination. Representative band profiles of PCR product are shown
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in Figure 3.1. Those shown are an average representation of each group. All profiles 
in each group were within + or -1 band range except day 2 rejecting and 0X38 anti- 
CD4 treated IL4 profiles in which 75% and 50% respectively showed no bands at 
all. The p actin product bands shown are of day 5 rejecting and 0X38 anti-CD4 
treated grafts and can be seen to be equivalent. The p actin band profiles of all other 
samples used gave similar patterns and intensities. Semi-quantitative analysis on all 
samples was carried out by comparing and contrasting product band intensities.
IL2
All rejecting heart grafts tested showed detectable levels of IL2 mRNA rising from 
day 2 to peak at day 5 post-transplant. Although day 7 grafts had similar bands to 
day 5 grafts, they were not as intense, suggestive of a slight diminution of IL2 
production at the terminal stage of the rejection process. 0X38 anti-CD4 treated 
grafts showed broadly similar levels of IL2 transcripts to rejecting grafts except on 
day 7 post-transplant where antibody treated grafts showed shghtly more bands with 
a slight increase in their intensity. Grafts from the CsA treated rats showed either a 
minimal amount of detectable transcript or none at all, while DSBT treated grafts 
gave only a few very weak bands.
IL4
Like IL2, IL4 transcripts in rejecting grafts peaked at day 5 post-transplant and 
although still detectable by day 7, the band intensity had diminished considerably. 
Unlike IL2 however, only 25% of the day 2 grafts showed any detectable levels of
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IL 2 IL 4
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IL 2  IL 4
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Figure 3.1 In tragraft IL2, IL4 and Actin mRNA expression of 
Rejecting and Tolerised Lewis heart allografts from DA recipients by
PCR. Lewis hearts were excised at days 2,5 and 7 post transplant from 
DA recipients which were either unmodified, or had been rendered 
tolerant by DSBT, Cyclosporin A or 0X 38 anti-CD4 treatment. The tissue 
was homogenised, and cDNA prepared from each sample which was then 
amplified by PCR using appropriate primer pairs. Reaction products were 
analysed by gel electrophoresis and ethidium bromide staining and viewed 
under UV transillumination. Profiles shown are an average representation 
of each group. All profiles in each group were within + or - 1 band range 
with 2 exceptions (see 4.2 ).
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IL4 mRNA and even then, the bands were so weak to be barely perceptible, even at 
the highest cycle numbers. In 0X38 anti-CD4 treated rats, only 50% of the day 2 
post-transplant grafts gave measurable but weak bands. By day 5, all four grafts 
showed bands at all cycle numbers and on day 7, although the band intensities had 
diminished, all grafts still had detectable levels of transcript. The grafts from CsA 
treated rats had very low levels of transcript whereas grafts from the DSBT treated 
rats had detectable cytokine levels at the highest three cycle numbers.
Summary
IL2 transcripts peaked at day 5 post-transplant in rejecting grafts compared to day 7 
in 0X38 treated grafts. IL4 mRNA was virtually undetectable at day 2 post­
transplant in rejecting grafts, but rose dramatically to peak at day 5 before receding 
again, a scenario remarkably similar to that seen in the antibody treated grafts. In the 
CsA treated grafts, IL4 transcripts which although weak, were perceptible compared 
to those of IL2 which were virtually non-existent. In DSBT treated grafts, both IL4 
and IL2 transcripts were relatively weak with the former, if anything, shghtly the 
stronger.
4.3 Discussion
By using the PCR technique to detect EL2 and IL4 cytokine gene expression in the 
cardiac allografts, it has enabled small but equivalent amounts of RNA from each 
tissue to be amplified sufficiently to compare and contrast the levels of cytokine 
production in both the rejecting and tolerant grafts by observing both the number 
and the intensities of the positive bands. Direct comparisons between IL2 and IL4
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levels of expression is made more difficult by the fact that higher cycle numbers were 
used to amphfy the IL4 message compared to the IL2 to attempt to try and 
compensate for the expected low levels of JL4 transcripts experienced previously in 
our laboratory, and by others (M^Knight et al, 1991).
As was to be expected by its reported mode of action, CsA treated grafts 
showed no perceptible levels of IL2 transcript expression. IL4 message was detected 
but it was not strong, suggesting that CsA treatment preferentially affects Thl 
transcripts by downregulating them whilst affording a degree of protection towards 
the transcripts of Th2-like cells. Takeuchi et al, (1992), made similar findings while 
using fully mismatched mouse heart grafts. Weak positive IL2 transcripts were found 
only on day 4 post-transplant while IL4 transcripts were found to be more abundant 
on days 4 and 5, before diminishing. Some groups however have shown that Th2 
cytokine production (e.g. IL4) may also be inhibited by CsA (Gajewski et al, 1990), 
and this may be a plausible reason for its weak expression seen in the experiments 
reported here.
Transcripts for both IL2 and IL4 were detected, albeit weakly in allografts 
from DSBT treated recipients at day 5 post-transplant. These results follow a similar 
pattern although at a lower order of intensity to Takeuchi et al, (1992), who 
reported comparable levels of both IL2 and IL4 transcripts at day 4 post-transplant 
with the IL2 diminishing at day 6, and IL4 increasing to peak at day 14 post­
transplant. Also noted was a 10^20 fold reduction in IL2 transcripts in the 
transfused recipients in comparison to rejecting grafts. However, Dallman et al.
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(1991), also comparing rejecting and DSBT treated grafts found that cells isolated 
from both sets of grafts showed broadly similar levels of IL2 transcripts, but that no 
IL2 was produced by the tolerised cells, concluding that tolerance was caused by 
alteration in the IL2 production pathway.
The finding of maximum IL2 transcript expression on day 5 post-transplant 
in rejecting grafts has been documented by other groups also using fully mismatched 
cardiac allografts models (Morgan et al, 1993 & Takeuchi et al, 1992), and these 
same groups noted, as we did, the appearance of IL4 transcripts on day 5, 
diminishing by day 7 post-transplant. These results, coupled with the findings of 
Krams et al, (1992), who found IL2 positive transcripts in less than 20% of rejected 
human kidneys, but that 46% of these same kidneys contained JL4 positive 
transcripts, shows that although Thl-type cytokines e.g. IL2 are necessary to 
promote cytotoxic cell activation and thus bring about graft destruction, the presence 
of Th2-type cytokines may also be necessary, e.g. to stimulate B cell production of 
alloantibodies.
In the experiments reported here, IL2 and IL4 transcripts both followed 
similar patterns of appearance in the 0X38 anti-CD4 treated grafts. The appearance 
of IL2 transcripts in the graft showed that IL2 production did not appear to be 
inhibited by the antibody therapy and, indeed, the IL4 transcripts seemed to be 
enhanced, similar to results reported by Takeuchi et al, (1992). In comparing 
rejecting and antibody treated grafts, there is a marked similarity in the intragraft 
expression of both IL4 and IL2 transcripts, with the pattern and intensity of EL2
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transcripts in rejecting grafts being mirrored in the antibody treated ones. IL4 
transcripts appeared earlier post-transplant in antibody treated grafts than in rejecting 
ones where they were virtually undetectable. By day 5, both rejecting and antibody 
treated grafts expressed significant levels of EL4 mRNA, with the antibody treated 
grafts showing slightly more intense bands although this may be caused in part by the 
higher cycle numbers used in the IL4 amphfication than in the IL2 one.
It would appear from the above findings that the main hallmark of 
tolerance induction in all three models used here is the preservation and/or 
enhancement of IL4 transcripts suggesting that the more ‘protective’ Th2-like cells 
play a crucial role in the maintenance of the tolerant state, while the early appearance 
of IL2 transcripts brings about the onset of irreversible rejection of the allograft.
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Chapter 5
Development and Application of an 
In situ Hybridisation method to detect 
cytokine mRNA expression in frozen sections 
of rejecting and tolerant rat heart allografts
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5.1 Introduction
The use of In-situ Hybridisation to identify specific mRNA sequences in tissue 
sections or single cell suspensions has allowed individual cells that express the target 
sequence of interest to be localised microscopically with great accuracy. Early 
methods using isotopically labelled DNA or RNA probes while very sensitive, also 
posed various problems, not least the potential hazard to health (Larsson, 1989). 
Important prerequisites for the success of the technique include probe specificity to 
and preservation of tissue target mRNA sequences. The more recent use of 
commercially manufactured non-isotopically labelled synthetic oligonucleotide 
probes has increased the reproducibihty of the technique while at the same time, 
shortening the overall timescale involved (Larsson and Hougaard, 1990). These anti­
sense oligoprobes can be specifically matched, using computer software, to any exon 
of the complimentary target mRNA sequence. Although they are only a fraction of 
the size of an average RNA probe, they may be combined in cocktails of oligoprobes 
specific for different areas of the target sequence to give similar levels of sensitivity.
An essential component of the ISH method is the pre-optimisation of the 
various stages of the technique. This involved testing different hybridisation 
temperatures, buffers, fixatives and post-hybridisation stringency washes to try and 
ensure maximum probe sensitivity and minimum background staining.
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Fixatives and Pretreatments
The cross linking fixative paraformaldehyde as a 4% solution was the fixative of 
choice for both frozen sections and cell smears, and as the solution was treated with 
DEPC, a ribonuclease inhibitor, fixation was carried out at room temperature rather 
than at 4®C (also inhibits endogenous ribonucleases). Twenty minutes in the fixative 
was enough to ensure preservation of the tissue and allow probe access to target 
sequences, whereas times greater than forty minutes were found to decrease signal 
due to possible overfixation causing dense cross-linking of tissue proteins.
Longer fixation times can be used, but this often requires the use of acids 
e.g. hydrochloric, or proteases e.g. proteinase K in solution to digest away some of 
the cross-linking, thus allowing probe access, but the amount used must be carefully 
titrated. Both were utilised, but the use of acid on frozen sections caused destruction 
of the tissue and the varying concentrations of enzymes used (1—>10|Xgs/ml) led to 
overdigestion of the tissue section causing non-specific stickiness of probe when 
applied. Cell smears, however, did appear to benefit from the use of enzyme at the 
lowest concentration (Ip-g/ml) for fifteen minutes at 37®C.
After the removal of fixative by several washes in DEPC treated PBS, a 
pre-hybridisation step using the hybridisation buffer minus probe for thirty minutes 
under hybridisation conditions, favoured by some groups, was found to be 
unnecessary as its usage did not alter the results. All sections were then dehydrated 
through increasing concentrations of absolute alcohol diluted with DEPC/H2O and 
air dried. This step was found to increase the signal intensity, probably by ensuring 
that the probe was not diluted by any fluid on the tissue section.
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Hybridisation buffers and Conditions
Hybridisation was carried out various temperatures room temperature, 37°C, 40°C 
and 42®C using a variety of buffers containing a variety of ingredients and it was 
found that 37°C was the optimum hybridisation temperature. Room temperature 
hybridisations led to a slight increase in background staining whereas 40°C and 42®C 
hybridisations led to less specific signal being recorded. Several buffers containing 
varying concentrations of deionised formamide (20—>50%) were tried, but all gave 
rise to a distinctive background brown colouration to the tissues. Formamide is used 
to allow hybridisation at lower temperatures (especially good for longer RNA 
probes), but was found to be unbeneficial using our shorter oligoprobes so was 
removed from the buffer ingredients.
The use of higher concentrations of SSC in the buffer (4x) ensures binding 
stability of probe to target sequence, as did the addition of 5mg/ml sodium 
pyrophosphate. As no prehybridisation step was included, it was imperative to 
ensure that any non-specific binding of the probe was kept to a minimum or blocked 
completely during the overnight hybridisation. Denhardts reagent, containing BSA, 
ficoll and polyvinylpyruvate, as well as denatured salmon sperm DNA, were included 
in the buffer to achieve this. The inclusion of 0.5mls of 50% dextran sulphate, a 
volume exclusion agent, to effectively increase the probe concentration and rate of 
hybridisation was also found to be beneficial by shghtly increasing the positive signal 
without causing any background staining or non-specific binding. Other additives 
e.g. Yeast RNA, sodium dodecyl sulphate (an RNAse destroyer) and tris-HCL pH
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7.5 buffer were also tried but gave no added benefit, so were omitted from the final 
hybridisation buffer decided upon (see appendix 2 ).
Probe concentrations were very important and a series ranging from 
0.1-^lng/|il were used. 0.5ng/|il was found overall to be adequate in most cases and 
in slides where no signal was found, the probe concentration was increased, usually 
to no avail except with the addition of general background staining.
Post Hybridisation and Detection
Post hybridisation washes are designed to remove any hybrids formed between 
imperfectly matched sequences, so washes at room temperature at a lower SSC 
concentration than used during hybridisation followed by a high stringency wash at 
45°C were found to be necessary to remove unwanted hybrids. Failure to use the low 
salt concentrations usually led to an increase in background staining.
Anti-digoxigenin antibody at 1.5mU/ml, and substrate solutions, were used 
as per manufacturers instructions. The antibody was used after a blocking stage 
designed to ensure no non-specific binding of the antibody, although the antibody 
solution itself also contained normal sheep serum which should have the same effect. 
Colour development of the signal catalysed by the substrate solution had to be 
checked microscopically in every experiment, and the experiment halted when an 
adequate colour intensity appeared. Generally, colour development was sufficient 
after about one hour, but samples with no specific signal were checked periodically 
and sometimes left in a dark cupboard overnight in case colour development was for
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some reason very slow. These samples never showed any signal, and the colour was 
often grossly overdeveloped.
Once all these stages had been ironed out, a general method came into 
shape and was used for all the samples. This was used to localise cytokine mRNA 
production in the tissues and relate it to graft infiltrate as this gives more information 
about cytokine production than simply measuring secreted protein in peripheral 
blood. At the time of initiating this project, it still was not clear what cytokines were 
produced, and by which cells, in the response to the transplantation of an allograft, 
and it was thought that studying the pattern of certain signal cytokines in both 
rejecting and tolerised grafts might help elucidate the picture.
In the set of experiments carried out here, probe specificity to target 
mRNA sequence was confirmed by hybridising the relevant oligoprobes with 
cytospin preparations of transfected Chinese hamster ovary(CHO) cells. These cells 
constitutively synthesise and secrete high levels of recombinant rat IL2 or IL4 
cytokines (M'^Knight and Classon, 1992). Oligo d(T) probes which specifically bind 
to the poly A tail of mRNAs were used as positive controls in every experiment to 
verify the integrity of the mRNA. Negative controls were also used and these 
included hybridisation buffer solution minus any probe and occasionally an irrelevant 
human anti-sense Insulin probe, used under the same conditions as the specific IL2 
and IL4 probes.
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5.2 Results
Heart allografts from rejecting and 0X38 anti-CD4 treated rats were sampled on 
days 2, 5 and 7 post-transplant, while DSBT and CsA treated rat heart allografts, as 
well as syngeneic control grafts were available on day 5 post-transplant only. AH 
hearts utihsed were Lewis strain hearts that had been transplanted into DA 
recipients(i.e. Lewis^DA).
After the rats had been sacrificed, the hearts were removed immediately 
and divided up. The portion for ISH was then placed in tissue-tek O.C.T embedding 
medium and immediately snap frozen in liquid nitrogen. 5 micron(pm) sections were 
cut of each tissue on a cryostat at -20"C, mounted on subbed slides and immediately 
fixed at room temperature in 4% paraformaldehyde to ensure the preservation of 
tissue morphology and the mRNA transcripts being studied. The intragraft 
expression of IL2 and IL4 mRNA sequences was analysed by hybridisation with 
specific non-isotopically labelled anti-sense oligonucleotide probes for IL2 and IL4. 
The specificity of the probes for their targets had been confirmed using CHO IL2 
and IL4 secreting cell line smears (Figure 4.1).
The poly d(T) probe included in every experiment was consistently positive 
(Figure 4.2a), confirming the integrity of the mRNA sequences of the tissue under 
investigation and also that the conditions used were indeed favourable for 
hybridisation to target sequences to take place. Hybridisation buffer negative 
controls, also included in each experiment were always clear (Figure 4.2b), as were 
sections using the irrelevant insulin probe when used. This confirmed that any 
endogenous alkahne phosphatase present in the heart tissue had indeed been
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Figure 4.1 Positive labelling of an IL4 secreting CHO cell line smear using a 
Digoxigenin labelled anti-sense IL4 oligonucleotide probe cocktail. (x200)
Hybridisation of probe to relevant target sequences was used to confirm probe 
specificity. Similar results were obtained using an anti-sense IL2 oligonucleotide 
probe cocktail against an IL2 secreting CHO cell line. No counterstain.
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Figure 4.2 Positive and Negative ISH Controls.
Cryostat sections of Lewis heart allografts from DA recipients were hybridised with
a) Top - (xlOO) Poly d(T) probe as positive control.
b) Bottom - (x200) Hybridisation Buffer alone as negative control.
These controls were used in each experiment to verify mRNA integrity and confirm 
the absence of endogenous tissue alkaline phosphatase. No counterstain.
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inhibited by the levamisole, which had been added to the NBT/BCIP solution for that 
purpose. After an overnight hybridisation, any non-specifically bound probe was 
removed by washes of increasing stringency before the administration of the 
NBT/BCIP/levamisole solution to enable the visualisation of the remaining 
specifically bound probe by optical microscopy.
IL2
IL2 positive signal occurred in all rejecting grafts (days 2, 5 and 7) post-transplant 
(Figures 4.3 and 4.4), increasing in frequency and intensity over the time span 
studied. As can be seen in Figure 4.4, day 7 rejecting grafts were characterised by 
gross tissue damage and irrespective of the stringency of the post-hybridisation 
washes, it was impossible to remove all non-specific binding due to the apparent 
stickiness of the tissue causing an apparent overstaining of the tissue sections. 
Syngeneic grafts (n=2) as well as allografts from CsA treated recipients (n=2) were 
both negative for IL2 irrespective of the probe concentration used, whereas grafts 
from DSBT treated recipients on day 5 (n=2) showed similar levels of IL2 mRNA to 
day 2 rejecting grafts (Figure 4.5). Positive staining for IL2 in 0X38 anti-CD4 
treated grafts was much more variable and was observed only in one of four grafts 
harvested on day 2, one of four day 5 grafts and two out of four day 7 grafts (Figure 
4.6).
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%Figure 4.3 (Top) Positive IL2 labelling of a Day 5 Rejecting Lewis Heart 
Allograft from a DA recipient. (x200)
Cryostat sections of Lewis hearts, excised 5 days post transplant from DA recipients 
(n=4) were hybridised overnight with a Digoxigenin labelled anti-sense IL2 
oligonucleotide probe cocktail. No counterstain.
Figure 4.4 (Bottom) Positive IL2 labelling of a Day 7 Rejecting Lewis Heart 
Allograft from a DA recipient. (x400)
Cryostat sections of Lewis hearts, excised 7 days post transplant from DA recipients 
(n=4) were hybridised overnight with a Digoxigenin labelled anti-sense IL2 
oligonucleotide probe cocktail. No counterstain. Note severe tissue damage.
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Figure 4.5 (Top) Positive IL2 labelling of a Day 5 Lewis Heart Allograft from a 
DA recipient Tolerised by a DSBT. (x200)
Cryostat sections of Lewis hearts, excised from donor blood transfused DA 
recipients 5 days post transplant (n=2) were hybridised overnight with a Digoxigenin 
labelled anti-sense IL2 oligonucleotide probe cocktail. No counterstain.
Figure 4.6 (Bottom) Positive IL2 labelling of a Day 7 Lewis Heart Allograft 
from a DA recipient Tolerised by an 0X38 Anti-CD4 antibody regimen. 
(x2 0 0 )
Cryostat sections of Lewis hearts, excised from 0X38 Anti-CD4 treated DA 
recipients 7 days post transplant (n=4) were hybridised overnight with a Digoxigenin 
labelled anti-sense IL2 oligonucleotide probe cocktail . No counterstain.
IL4
Positive IL4 mRNA staining could only be found in two day 5 rejecting grafts (n=4) 
(Figure 4.7), and even then only weakly. No other graft, DSBT, CsA or 0X38 anti- 
CD4 treated or syngeneic control grafts showed any positive staining.
Summary
ISH identified IL2 mRNA positive cells in all rejecting grafts but only in some 
0X38 anti-CD4 treated grafts (33% overall). No positive staining was found in CsA 
treated or syngeneic grafts whereas DSBT treated grafts were weakly positive. IL4 
mRNA was only detected in 50% of day 5 rejecting grafts utihsing the same 
hybridisation conditions as DL2. The pattern of staining was consistent with a diffuse 
cellular distribution.
5.3 Discussion
Both isotopically and non-isotopically labelled anti-sense probes have been used to 
study the cytokine mRNA repertoire of CD4^ and CD8 ^  cell subsets e.g. after 
mitogenic stimulation (Cardell et al, 1991, Sander et al, 1991 & Knight et al, 
1991), in anti-CD4 therapy in mice (Field et al, 1992), and in various experiments 
comparing allograft rejection and tolerance (Martinez et al, 1993, Yard et al, 1994 & 
Bugeon et al, 1992) to try and ascertain if the production of various cytokines 
correlated with either state.
In the set of experiments reported here using digoxigenin labelled 
oligonucleotide probes, graft rejection seemed to be associated with a sequential rise 
in intragraft IL2 mRNA expression by infiltrating cells from day 2 to day 7
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Figure 4.7 Positive IL4 labelling of a Day 5 Rejecting Lewis Heart Allograft 
from a DA recipient. (x200)
Cryostat sections of Lewis hearts, excised 5 days post transplant from DA recipients 
(n=4) were hybridised overnight with a Digoxigenin labelled anti-sense IL4 
oligonucleotide probe cocktail. No counterstain.
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post-transplant with rejection occurring immediately afterwards. This in itself would 
tend to suggest that rejection, in this model of high responder donors and low 
responder recipients is driven by the presence of committed Thl cells releasing IL2 
and probably IFNy leading to the activation of macrophages and cytotoxic T cells. 
The presence of IL4 on day 5, released by the more protective Th2 subset in no way 
detracted from the ongoing process of rejection and it is possible that the rejection 
process was driven by a combination of the actions of both Thl and Th2 subsets, as 
has been postulated elsewhere (Dallman, 1995).
The complete absence of IL2 transcripts in the grafts of CsA treated rats is 
not surprising as one of the main modes of action of the drug is the inhibition of IL2 
production by activated T cells (Elliot et al, 1984), and has been shown to occur at 
the pre-transcriptional level (McCaffrey et al, 1993). The lack of detectable IL4 
mRNA transcripts in these grafts is shghtly puzzhng as it has been reported that Th2 
clones, (IL4 producing), may be more resistant to the actions of CsA than Thl 
clones, and that negating the action of these Thl-like ceUs may alter the Thl/Th2 
balance in favour of the latter (Gajewski et al, 1990). It would therefore be probable 
that IL4 should have been detected albeit at low levels. It is also possible that as only 
day 5 post-transplant samples were available here, that IL4 production had peaked 
earlier or later than the time sampled and would have been strong enough to be 
detected.
The same scenario may account for the lack of IL4 mRNA transcripts 
found in DSBT grafts which again were only available on day 5 post-transplant. 
Some expression, even at low levels, might have been expected as some studies have
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shown that Th2-like cells persist in grafts from animals tolerised by transfusion 
causing suppression of the Thl-like cells (Takeuchi et al, 1992), which could 
account for the low level of IL2 mRNA transcripts recorded here in comparison to 
day 5 rejecting levels.
The complete absence of positive IL4 mRNA signal in the 0X38 anti-CD4 
treated grafts is enigmatic, as evidence from several groups has shown that Th2-like 
cytokine expression is preserved or even enhanced in the grafts of non-depleting 
antibody treated animals at the expense of IL2R positive cells and Thl-like cytokine 
(IL2 and IFNy) expression, which has been shown to decrease (Siegling et al, 1993 
& Mottram et al, 1995). This may account for the findings here i.e. that IL2 message 
was only detectable in 25% of day 2, 25% of day 5 and 50% of day 7 grafts. The 
lack of detection, especially of IL4 transcripts may lead to the assumption that the 
ISH method itself is just not sensitive enough to record low levels of transcript even 
after repeated attempts using different hybridisation parameters e.g. probe 
concentrations and hybridisation temperatures etc. Similar problems have however 
been reported by others. Unlike IL2 and IFNy transcripts, IL4 mRNA expression in 
Con A stimulated rat C D 4^ cells could not be detected using radiolabelled probes, 
and it was concluded that this was due to the low level of IL4 gene expression, also 
noted in mice and humans (M^^Knight et al, 1991). IL2 transcripts, especially in 
rejecting grafts was obviously strong enough, with enough copy numbers/cell to be 
detected with relative ease, but in 0X38 anti-CD4 treated grafts, differentiation 
between weakly positive cells and any background staining was more problematical.
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Chapter 6
Final Discussion
121
6.1 Discussion
In the experiments described in this thesis, we sought to analyse intra-graft 
expression of the cytokines IL2 and IL4 produced by Thl and Th2 subsets 
respectively of activated T cells using molecular biological methods to compare their 
appearance in rejecting and tolerised rat heart allografts at various time points post­
transplantation.
Before the specific analysis of the IL2 and IL4, it was important to study 
allograft cellular infiltrates by hght microscopy of tissue sections labelled with 
specific monoclonal antibodies. This not only confirmed the presence of graft 
infiltrating cells, including cells likely to produce the Thl and Th2 signature 
cytokines, but also allowed the kinetics of graft infiltration to be studied in both the 
rejecting and tolerised graft models.
Studying the results of the phenotypic analysis of the infiltrate appears to 
show that in the Lewis—>DA rejecting model used here, rejection is characterised by 
high levels of OX39(IL2Ra) positive T cells and EDI positive macrophages in a 
Thl-type environment. In spite of the presence of a dense graft infiltrate of 
mononuclear cells containing large numbers of CD8  ^ cytotoxic T cells and EDI 
positive macrophages in allografts from animals tolerised by DSBT, anti-CD4 and 
CsA regimens, no rejection occurred. This may be associated with the much reduced 
levels of 0X39 positive and C D 4^ cells seen in these grafts which may cause a shift 
in Thl/Th2 cytokine balance towards a more protective Th2-type environment in 
these models as has been reported by other groups (Siegling et al, 1993 & Takeuchi 
et al, 1992). As these immunohistochemistry techniques could not differentiate
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between Thl-type and Th2-type cells, more sensitive methods were utilised which 
could detect typical cytokines from each subset e.g. IL2 from Thl-type and IL4 from 
Th2-type.
The In-situ Hybridisation technique used allowed direct cytokine mRNA 
expression to be identified within cells of each tissue. The method however has 
several reported drawbacks. It has been shown to be insensitive (Daha et al, 1994 & 
IVf^Knight et al, 1991), and reproducibility to be problematical (Fealy et al, 1995).
The PCR method used is much more sensitive and can detect lower levels 
of message than ISH. The cytokine mRNAs were analysed in total mRNA extracted 
from tissue and were likely to be produced only by infiltrating cells, thus when 
comparing equivalent amounts of total mRNA, variations in cytokine mRNA content 
were likely to reflect varying proportions of cellular infiltration at different time 
periods post-transplant. This has several drawbacks. As the method relies on 
homogenised tissue samples, it can only therefore record average mRNA levels in 
the tissue being analysed and is incapable of detecting important differences in 
activation in small subsets of T cells (Bugeon et al, 1992). It is also possible, in 
samples taken shortly after transplantation of the allograft that the isolated RNA in 
the homogenised extract may contain passenger leukocytes which accompanied the 
transplanted organ and therefore a true picture of the allospecific immune response 
at its onset may be difficult to ascertain.
A major concern when analysing mRNA transcripts, especially cytokines 
like IL2, is that they have been shown to have a very short half-life due to the 
presence of AU-rich consensus sequences in the 3' untranslated region of the mRNA
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and are quickly degraded in the cytoplasm following translation (Dallman et al, 1992 
& Fealy et al, 1995). In order to rninirnise the risk of RNA degradation, samples for 
ISH and PCR methods were immediately encased in tinfoil following extraction and 
snap frozen in liquid nitrogen, thus avoiding tissue destruction prior to processing. 
Immediate freezing of the tissue was preferred to fixation as the time taken for 
paraformaldehyde fixative to diffuse into the heart tissue could not be guaranteed to 
be uniform, therefore, the possibility could not be excluded that transcripts at the 
outer areas of the subsequent tissue sections might be better preserved than those 
towards the centre.
The oligo d(T) probe and the P actin PCR samples, used as positive 
controls in the ISH and PCR methods respectively show only that mRNA sequences 
have been preserved in general and cannot confirm the status of the distinct cytokine 
sequences of interest and it is probable that some may be lost in the process. This is 
probably more crucial in the In-situ method as low levels of cytokine mRNA 
message can be difficult to distinguish from background staining (Krams et al, 1992) 
or in the case of IL4, to be detected at all (M'^Knight et al, 1991).
Comparing results obtained using both ISH and PCR methods on the same 
sample is difficult. In the ISH results reported here, only day 5 rejecting hearts 
showed any detectable levels of IL4, and even then in only 50% of the grafts. Using 
the PCR method on the same tissue, all four grafts were positive for IL4 transcripts. 
Day 2 rejecting graft IL4 results were similar for both methods in that none was 
detectable in either. Most PCR EL4 results from tolerised grafts showed that IL4 was 
only weakly expressed in these grafts with the exception of day 5 anti-CD4 treated
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grafts which showed similar levels of transcript to day 5 rejecting grafts, some of 
which were positive by ISH. The lack of positive signal by ISH in these grafts is 
puzzling but it is possible that this may be due to large numbers of Th2 cells 
producing very small amounts of IL4 as opposed to a smaller number of cells making 
larger amounts of the cytokine, thus making it very difficult to be detected by the 
less sensitive ISH method as compared to the PCR. With IL2, detection rates using 
ISH and PCR were broadly similar in rejecting, CsA and DSBT grafts. The only 
discrepancy was in anti-CD4 treated grafts where only 25% of day 2, 25% of day 5 
and 50% of day 7 grafts were positive for IL2 by ISH, whereas by PCR, all grafts 
tested were positive although some, e.g. day 2, were fairly weak. This, like the IL4 
results may also be due to low levels of transcript produced by cells causing 
difficulties in detection especially when background staining was evident.
Combining the results obtained using both ISH and PCR methods to 
ascertain if a distinct Thl or Th2-like pattern can be characterised in either the 
rejecting or tolerant models used, seems to suggest that rejection in this Lewis—>DA 
strain combination is driven by cells of the Thl (IL2 producing) lineage. These cells 
seem to appear much earlier in the rejection process than cells of the Th2 (IL4 
producing) lineage, whose initial appearance on day 5 post-transplant cannot stop 
the already committed Thl cells from producing cytokines such as IL2 and IFNy. 
These cytokines can stimulate macrophages and CD8  ^ cytotoxic T cells to bring 
about irreversible graft destruction in spite of the presence of the more protective 
Th2 cytokines like IL4, a scenario that has also been shown by other groups (Krams 
et al, 1992 & Hancock et al, 1993).
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The virtual ablation of IL2 production seen in grafts tolerised by CsA here 
is in line with most other groups findings as the mode of action of the drug is the 
inhibition of IL2 production (Takeuchi et al, 1992). The production of IL4 also 
seems to have been slightly affected as has been reported previously (Gajewski et al 
1990). DSBT treated grafts showed minimal effect on IL4 production but a 
reduction in IL2 mRNA expression, and this is in general agreement with findings by 
others (Bugeon et al, 1992). The use of the non-depleting 0X38 anti-CD4 
monoclonal antibody to induce tolerance brought about a slight decrease in IL2 
production by Thl-like cells compared to levels in rejecting grafts sampled at a 
similar time scale while IL4 produced by the Th2-like cells was, if anything, 
enhanced. These findings show that total depletion of C D 4^ cells is not necessary 
to obtain tolerance in this model and that the antibody seemed to preferentially target 
Thl-like cells whose actions seemed to be slightly suppressed, while at the same time 
enhancing or sparing the functions of the Th2-like cells, findings similar to those 
reported by Siegling et al, (1993), and Kupiec-Weglinski et al, (1993).
However, both methods, even when used in tandem, can only confirm the 
presence or absence of the specific transcript under investigation, and cannot prove 
that the specific mRNA transcript has been translated into a biologically active 
molecule. Dallman et al, (1991),using DSBT induced tolerance in a rat renal allograft 
model recorded that both rejecting and tolerant grafts contained similar levels of IL2 
mRNA but that cells isolated from the tolerant rats could not make biologically 
active IL2, compared to the high levels of the cytokine produced in the rejecting 
rats, and postulated a post-translational alteration to the IL2 production pathway and
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showed that tolerance in that particular model could be abrogated by the addition of 
recombinant IL2.
All three methods used here to tolerise recipients to fully mismatched heart 
allografts show that tolerance seems to be accompanied by a preserved or heightened 
Th2-type response at the expense of the Thl-type whereas the earlier appearance of 
Thl-type cytokines in rejection, compared to the Th2-type, may predispose the 
irreversible onset of rejection in this model, despite the presence of Th2-type 
cytokines.
From the results recorded here, it may be concluded that the use of both 
ISH and PCR methods in detecting IL2 and IL4 intragraft transcripts is beneficial. 
Although ISH has emerged as a less sensitive technique than PCR, it has the abihty 
to allow individual cell expression of transcripts to be viewed microscopically in the 
graft whereas the use of the much more sensitive and reproducible semi-quantitative 
PCR technique is necessary to detect low levels of transcript which are a 
consequence of some tolerising regimens used, and a combination of both techniques 
gives a better representation of the cytokine milieu in the graft at the time of study.
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Appendix
Buffers and Solutions
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Glycine Dilution Buffer (see 2.3.3)
IM Glycine / 0.3M NaCl pH 8 . 6
Glycine : 75gms
Sodium Chloride : 17.6gms
Sterile Deionised Water : to 1 Litre
5M Sodium Hydroxide : sufficient to adjust pH to 8 . 6
Glycine Binding Buffer (see 2.3.3)
IM Glycine/0.15M NaCl pH 8 . 6
Glycine : 75gms
Sodium Chloride : 8 .8 gms
Sterile Deionised Water : to 1 Litre
5M Sodium Hydroxide : sufficient to adjust pH to 8 . 6
Citrate Buffer (see 2.3.3)
O.IM Citrate
Citric Acid monohydrate : 21gms
Sterile Deionised Water : to 1 Litre
5M Sodium Hydroxide : sufficient to adjust pH to 3.0
DEPC treated H2O. (see 2.6.2 etc.)
2mls of DEPC (Diethylpyrocarbonate) is added to 2 Litres of Deionised water, left 
for 24 hours and sterilised by autoclaving for 30 minutes at 136°C and 2.2bar. DEPC 
inhibits RNAses and DEPC treated water is used to make solutions in the 
Hybridisation methods.
SSC (Saline Sodium Citrate) Solution (see 2.6.2 etc.)
Stock Solution of 20xSSC
IxSSC = 0.15M NaCl / 0.015M NaCitrate pH 7.0
Sodium Chloride : 350.6gms
Sodium Citrate : 176.4gms
DEPC / H2O : to 2 Litres
5M Sodium Hydroxide : sufficient to adjust pH to 7.0
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Tris Hydrochloride Buffer pH 7.5 (see2.6.2 etc.)
Stock Solution of lOx (see below) -use at IX conc.= 0.15M NaCl / O.IM Tris-HCl
Tris-HCl : 157.6gms
Sodium Chloride : 87.7gms
DEPC / H2O : to 1 Litre
5M Sodium Hydroxide : sufficient to adjust pH to 7.5
Tris Hydrochloride Buffer pH 9.5 (see 2.6.2 etc.)
Stock Solution of lOx Tris-HCL (see below)-use at IX conc.= O.IM Tris-HCl
Tris-HCl : 157.6gms
DEPC / H2O : to 1 Litre
just before use, the following are added to IX Tris-HCl
Sodium Chloride : 5.844gms (= 0. IM)
Magnesium Chloride 6 H2O : 10.16gms (= 0.05M)
5M Sodium Hydroxide : sufficient to adjust pH to 9.5
Hybridisation Buffer (see 2.6.2 , 5.1 etc.)
20xSSC : 1ml
Denhardts solution : 0.5mls
Salmon Sperm DNA : 0.05mls
Sodium Pyrophosphate : 0.25mls
50% Dextran Sulphate : 0.5mls
DEPC /H2O : to 5 mis
Store at 4°C. Warm up to 37°C before use.
Loading Buffer (see 2.7.4)
DEPC/H2 0 : 70mls
Glycerol : 30mls
Bromophenol Blue : 0.4gms
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1.5% Agarose Gel (see 2.7.4)
1.5gms of Agarose (Sigma, UK) is dissolved in lOOmls of sterile 
deionised water in a microwave and allowed to cool slightly 
before being poured onto the gel apparatus and allowed to set 
with lane marker combs in situ.
Running Buffer (see 2.7.4)
A Stock Solution of 5xTBE is made up as follows:
Tris Base : 54gms (= 0.089M)
Boric Acid : 27.5gms (= 0.089M)
EDTA : 1.25gms (= 0.00125M)
DEPC/H2O : to 1 Litre
solution should be pH 8.3 without adjustment.
The above solution should be diluted 1/10 with sterile deionised 
water shortly before use = 0.5xTBE
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